Therapeutic efficacy of small molecule inhibitors of human respiratory syncytial virus (hRSV) in neonatal lambs by Sitthicharoenchai, Panchan
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2019
Therapeutic efficacy of small molecule inhibitors of




Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Pathology Commons, Pharmacy and Pharmaceutical Sciences Commons, and the
Veterinary Medicine Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Sitthicharoenchai, Panchan, "Therapeutic efficacy of small molecule inhibitors of human respiratory syncytial virus (hRSV) in
neonatal lambs" (2019). Graduate Theses and Dissertations. 17320.
https://lib.dr.iastate.edu/etd/17320
 
Therapeutic efficacy of small molecule inhibitors of  







A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
Major: Veterinary Pathology 
 
Program of Study Committee: 
Mark R. Ackermann, Co-major Professor 
Jesse M. Hostetter, Co-major Professor 
Rachel J. Derscheid 
Michael J. Yaeger 




The student author, whose presentation of the scholarship herein was approved by the 
program of study committee, is solely responsible for the content of this dissertation. The 
Graduate College will ensure this dissertation is globally accessible and will not permit 









Copyright © Panchan Sitthicharoenchai, 2019. All rights reserved. 
 ii 
DEDICATION 
This dissertation is dedicated to the late King of Thailand, 
His Majesty King Bhumibol Adulyadej. 
 iii 
TABLE OF CONTENTS 
Page 
DEDICATION .................................................................................................................... ii 
TABLE OF CONTENTS ................................................................................................... iii 
LIST OF FIGURES ............................................................................................................ v 
LIST OF TABLES ............................................................................................................ vii 
ACKNOWLEDGMENTS ............................................................................................... viii 
ABSTRACT ....................................................................................................................... ix 
CHAPTER 1. GENERAL INTRODUCTION ................................................................... 1 
Statement of the Problem .............................................................................................. 1 
Central Hypothesis and Specific Aims .......................................................................... 1 
Dissertation Organization .............................................................................................. 2 
Literature Review .......................................................................................................... 2 
Human Respiratory Syncytial Virus (hRSV) ........................................................... 2 
Viral classification and characteristics of hRSV .............................................. 2 
Epidemiology of hRSV infection...................................................................... 3 
Pathogenesis of hRSV: Viral load and host immune response ......................... 4 
Regulation of immune responses to hRSV ....................................................... 8 
Animal Models for hRSV and the Neonatal Lamb Model ....................................... 9 
Development of Vaccine and Therapeutic Agents for hRSV ................................ 12 
Vaccine development of hRSV ....................................................................... 13 
Therapeutic agents for prevention and treatment of hRSV ............................ 17 
References ................................................................................................................... 20 
CHAPTER 2.   THERAPEUTIC EFFICACY OF JNJ-53718678, A HUMAN 
RESPIRATORY SYNCYTIAL FUSION INHIBITOR, IN NEONATAL LAMBS ....... 42 
Abstract ........................................................................................................................ 42 
Introduction ................................................................................................................. 43 
Materials and Methods ................................................................................................ 44 
Results ......................................................................................................................... 52 
Discussion .................................................................................................................... 54 
Conclusions ................................................................................................................. 58 
Acknowledgments ....................................................................................................... 58 
Declaration of Conflicting Interests ............................................................................ 58 





CHAPTER 3.   EFFICACY OF THE HUMAN RESPIRATORY SYNCYTIAL 
VIRUS (HRSV) REPLICATION INHIBITOR JNJ-64166037 IN HRSV 
INFECTED LAMBS ........................................................................................................ 70 
Abstract ........................................................................................................................ 70 
Introduction ................................................................................................................. 71 
Materials and Methods ................................................................................................ 72 
Results ......................................................................................................................... 81 
Discussion .................................................................................................................... 85 
Conclusions ................................................................................................................. 89 
Acknowledgments ....................................................................................................... 90 
Declaration of Conflicting Interests ............................................................................ 90 
References ................................................................................................................... 90 
CHAPTER 4.    EFFICACY AND TIME WINDOW FOR TREATMENT WITH 
COMBINATION THERAPY OF THE HUMAN RESPIRATORY SYNCYTIAL 
VIRUS (HRSV) FUSION INHIBITOR AND NON-FUSION PROTEIN 
INHIBITOR IN HRSV INFECTED LAMBS ................................................................ 101 
Abstract ...................................................................................................................... 101 
Introduction ............................................................................................................... 103 
Materials and Methods .............................................................................................. 105 
Results ....................................................................................................................... 112 
Discussion .................................................................................................................. 119 
Acknowledgments ..................................................................................................... 124 
Declaration of Conflicting Interests .......................................................................... 124 
References ................................................................................................................. 124 
CHAPTER 5.    GENERAL CONCLUSIONS ...................................................... 145 
 v 
LIST OF FIGURES 
Page 
CHAPTER 2 THERAPEUTIC EFFICACY OF JNJ-53718678, A HUMAN 
RESPIRATORY SYNCYTIAL FUSION INHIBITOR, IN NEONATAL LAMBS 
Figure 1: Plasma compound levels of JNJ-5371867......................................................... 64 
Figure 2: Morphological changes of lungs and average gross hRSV-associated lung 
lesion ............................................................................................................. 65 
Figure 3: Microscopic lung lesions in hRSV-infected lambs and average 
microscopic consolidation score ................................................................... 66 
Figure 4: Immunohistochemical detection of hRSV antigen and immunoreactivity 
score .............................................................................................................. 67 
Figure 6: Cytokines and chemokines mRNA expression (IP-10, MCP-1, MIP-1α, 
PD-L1, IFN, RANTES and IL-13) ............................................................. 69 
 
CHAPTER 3 EFFICACY OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS 
(HRSV) REPLICATION INHIBITOR JNJ-64166037 IN HRSV INFECTED LAMB 
MODEL 
Figure 1: Plasma compound level of JNJ-64166037 ........................................................ 94 
Figure 2: Viral titer level in BALF and lung detected with focus forming unit assay 
(FFU) and RT-qPCR .................................................................................... 95 
Figure 3: Gross and microscopic lesions in lung in vehicle and replication inhibitor 
treatment groups ........................................................................................... 96 
Figure 4: Percentage of HRSV-associated lung lesion and HRSV-associated 
microscopic lung score ................................................................................. 97 
Figure 5: Immunohistochemical detection of hRSV antigen and RNA in situ 
hybridization ................................................................................................. 98 
Figure 6: Immunoreactivity score and RNA in situ hybridization H score of hRSV 
antigen .......................................................................................................... 99 
Figure 7: Cytokine and chemokine mRNA expression (IP-10, MCP-1, MIP-1α, PD-







CHAPTER 4 EFFICACY AND TIME WINDOW FOR TREATMENT WITH 
COMBINATION THERAPY OF THE HUMAN RESPIRATORY SYNCYTIAL VIRUS 
(HRSV) FUSION INHIBITOR AND NON-FUSION PROTEIN INHIBITOR IN HRSV 
INFECTED LAMB MODEL 
Figure 1: Pharmacokinetics of fusion and replication inhibitors in Phase I 
combination efficacy study ......................................................................... 131 
Figure 2: Pharmacokinetics of fusion and replication inhibitors in Phase II treatment 
time window study ..................................................................................... 132 
Figure 3: Phase I combination efficacy study viral titer in BALF and lung detected 
by FFU and RT-qPCR ................................................................................ 133 
Figure 4: Phase II treatment time window study viral titer in BALF and lung 
detected by FFU and RT-qPCR .................................................................. 134 
Figure 5: Clinical parameters assessment in Phase I and Phase II combination study ... 135 
Figure 6: Macroscopic lesions of lungs from Phase I combination efficacy study ........ 136 
Figure 7: Microscopic lesion in lungs of Phase I combination efficacy study ............... 137 
Figure 8: Immunohistochemical detection of RSV antigen and in situ hybridization 
detection of hRSV mRNA in lamb lungs from Phase I combination 
efficacy study .............................................................................................. 138 
Figure 9: Morphological lesions in the lung from Phase II treatment time window 
study ........................................................................................................... 139 
Figure 10: Macroscopic and microscopic hRSV-associated lung lesion from Phase II 
treatment time window study ..................................................................... 140 
Figure 12: Cytokine and chemokine mRNA expression (IP-10, MCP-1, MIP-1α, 
PD-L1, RANTES, IFN-, IL-13 and CC110) from Phase I and Phase II 




LIST OF TABLES 
Page 
Supplementary Table 1: Microscopic scoring criteria of hRSV infected lung . ............. 143 
Supplementary Table 2: List of RT-qPCR forward primers, reverse primers and 




I would like to extend my thanks to the most important person contributing to this 
work, my major advisor, Dr. Mark R. Ackermann, for accepting this foreign visiting 
scholar that walked into his office one day asking if she could do her PhD research with 
him and be part of his lab. Without him, the lamb projects would never have been possible. 
To every current and former Ackermann Lab members, whom with or without knowing it, 
have contributed one way or another to the making of this dissertation.  
I would also like to give my appreciation to all the committee members; Dr. Jesse 
Hostetter, for accepting and stepping in as the co-major advisor, Dr. Mike Yaeger, for his 
humor and care over my research work, future career and correct English language usage, 
Dr. Rachel Derscheid, for all her pre-existing work on the lamb projects and Dr. Marian 
Kohut, for her positive attitude and support. 
In addition, I would like to express thanks to my family for their long distance 
encouragements as well as my fellow colleagues and resident mates at the Department of 
Veterinary Pathology, Sarhad Alnajjar, Alyona Michael, Eric Cassmann, Jeba Jesudoss 
Chelladurai, Tyler Harm, Ariel Nenninger, Ya-Mei Chen and Saleh Albarrak, for their 
assistance throughout the course of my study and made coming to work feeling like going 
to a party even on the worst days. 
Lastly, I would like to give my most profound gratitude to Anandamahidol 




Human respiratory syncytial virus (hRSV) is a common cause of respiratory 
infection in human infants worldwide. Direct therapeutic methods for the prevention and 
treatment such as vaccination and antiviral therapy are limited. In studies within this 
dissertation, we determined the efficacy of orally administered small molecule fusion 
inhibitor and replication inhibitor in hRSV-infected neonatal lambs which model hRSV 
infection in infants. Furthermore, we evaluated the efficacy and treatment time window for 
administration of a combination treatment using both compounds. We determined that 
daily oral administration of small molecule fusion protein inhibitor (JNJ-53718678) and 
replication inhibitor (JNJ-64166037) first administered to hRSV-infected within 24 hpi, 
reduced the viral load and lung lesion in a dose-dependent manner. The combination 
treatment of both hRSV fusion inhibitor and replication inhibitor given at 24 hpi decreased 
the amount of virus and pulmonary lesion in a more profound manner than 
monotherapeutic administration of each compound. Interestingly, the delayed combination 
treatment starting at day 3 post infection demonstrated significant reduction of viral load 
and pulmonary lesion compared to monotherapy administered at similar time indicating a 
prolonged treatment time window. The small molecule inhibitor compounds used in this 
study are good therapeutic candidates for future tests in human clinical trials. 
In addition, we were able to quantify and localize the hRSV viral RNA with RNA 
in situ hybridization in the infected lung tissue as well as effectively quantify the amount 
of RNA expression by modification of RNAscope H scoring evaluation method using an 
image analyzer software. A new approach for assessment of cytokine expression in lung of 
infected lambs was performed by creating a baseline of cytokine expression of Memphis 
 x 
37 hRSV infected and non-infected lambs at 6 dpi through combining data from multiple 
lamb model studies. 
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CHAPTER 1.    GENERAL INTRODUCTION 
Statement of the Problem 
Human respiratory syncytial virus (hRSV) is a common cause of respiratory infection 
in infants and children worldwide [1]. This ubiquitous virus affects mainly the respiratory 
system causing rhinitis, bronchiolitis, pneumonia and occasionally otitis media. The most 
commonly susceptible individuals are children younger than 5 years old and over the age of 
65. Disease surveillance of hRSV determined that >57,000 children under the age of 5 years 
were hospitalized annually due to RSV-associated acute respiratory illness (ARI) [2]. The 
disease outcome can be severe and fatal in preterm infants and children younger than 1 year of 
age [1, 3, 4]. Approaches to prevent and treat hRSV includes vaccination, therapeutic 
antibodies, and antiviral drugs. Development of such therapeutic compounds and vaccines 
require extensive laboratory testing, animal trials in the preclinical stage and multiple phases 
of clinical trials. Our laboratory has established an hRSV-infected lamb model that has been 
proven suitable for many types of therapeutic and vaccination trials as well as pathogenesis 
studies [5-7]. The goal of this dissertation is to demonstrate the therapeutic efficacy of small 
molecule inhibitors of hRSV via intragastric administration in our neonatal lamb model of 
hRSV infection. 
 
Central Hypothesis and Specific Aims 
 By administering different types of therapeutic compounds, including monotherapy of 
fusion protein inhibitor, monotherapy of non-fusion protein inhibitor and combination of both, 
to groups of hRSV infected lambs, our central hypothesis is that these compounds will reduce 
the clinical signs, amount of hRSV pulmonary viral load and lesions in hRSV infected lambs. 
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To test this hypothesis, the following were determined in hRSV-infected lambs: 1) the efficacy 
of fusion protein inhibitor (JNJ-53718678), 2) the efficacy of non-fusion protein, replication 
inhibitor (JNJ-64166037), and 3) the efficacy and treatment time window when administrating 
combination of a fusion protein inhibitor and a non-fusion protein inhibitor. 
 
Dissertation Organization 
 This dissertation is divided into five chapters organized in the journal paper format. 
The first chapter (Chapter 1) describe the general knowledge and literature review related to 
the study. The following four chapters (Chapter 2-4) are individual manuscripts with references 
cited at the end of each chapter. The last chapter (Chapter 5) is the general conclusion. The 
first manuscript was published as part of an article in Nature Communications. The second and 
third manuscripts are prepared for submission to appropriate journal including Antiviral 




Human Respiratory Syncytial Virus (hRSV) 
Viral classification and characteristics of hRSV 
Human respiratory syncytial virus (hRSV), first discovered in 1956, is an enveloped 
non-segmented negative sense single stranded RNA virus. The virus belonged in the subfamily 
Pneumovirinae under Paramyxoviridae family, but have recently been reclassified into the 
family Pneumoviridae, genus Orthopneumovirus [8]. The hRSV virus is pleomorphic and 
covered by large glycoprotein spiked and herringbone-shaped nucleocapsid. The genome is 
15.2 kbp with 2 open reading frames, composed of 10 genes encoding for 11 proteins; 
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transmembrane proteins (G, F and SH), nucleocapsid protein (N), phosphoprotein (P), large 
polymerase protein (L), matrix protein (M), transcription factors (M2-1 and M2-2) and two 
non-structural proteins (NS1 and NS2). Infection of the virus is through the attachment of G 
and F protein and the entry is promoted by fusion of F protein with the host plasma membrane. 
Syncytial formation of infected cells initiated by F protein is a characteristic feature of this 
virus that mediates the spread of viral infection. 
 
Epidemiology of hRSV infection 
Respiratory syncytial virus mainly targets and infects the epithelial cells of the 
respiratory tract, and most commonly causes mild disease symptoms. However, in infants and 
older individuals, the disease can be severe and fatal resulting in hRSV associated 
bronchiolitis, hospitalization and death in some cases [9]. Infection at a young age, especially 
among infants less than 6 months of age, and in preterm infants are independent risk factors 
for hospitalization by hRSV due to severe bronchiolitis and pneumonia with an intense acute 
inflammatory response in the lower respiratory tract [2, 10]. Furthermore, this virus is the most 
common cause of hospitalized bronchiolitis in infants and children (60-80% of all cases) [2, 
11, 12], and along with human rhinoviruses, is one of the most common cause of acute 
respiratory infection (ARI) in infants [13, 14]. Most individuals (80-90%) are infected with 
hRSV at least once by two years of age [15]. Reinfections of the virus are common throughout 
life due to the short duration and partial protection of hRSV neutralizing antibody, though 
typically with milder clinical symptoms in uncomplicated cases [16, 17]. In addition to ARI, 
there is much evidence that support long-term respiratory problems, such as persistent or 
recurrent wheezing and asthma, associated with infants and children with history of hRSV 
lower respiratory tract infection and bronchiolitis [18-23]. 
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Another group of individuals susceptible to severe disease from hRSV infection is 
elderly adults and especially those of more than 65 years of age [24]. Initial outbreaks were 
reported in nursing homes in the late 1970s resulting in cases of pneumonia and deaths [25, 
26]. Further epidemiological and clinical data indicated elderly individuals with history of 
chronic heart and lung diseases are among high risk factors contributing to illness in this age 
group [27, 28]. 
 Similar to influenza virus, seasonality is an important factor for hRSV infection with 
patterns of infection during specific times of the year. Epidemiological data have demonstrated 
a peaked pattern of hRSV activity during winter months in the temperate zone, but more 
variability of timing and durations in the tropical climate [29-31]. The knowledge of 
seasonality of hRSV infection is not only essential for epidemiologic predictions, but also has 
implications for prophylaxis, prevention and control program especially in individuals with 
high risks of hRSV infection including preterm infants and children under 6 months of age at 
peak hRSV season [32-34]. 
 
Pathogenesis of hRSV: Viral load and host immune response 
The degree of severity with hRSV infection is related to many factors including the 
virus, host genetics contributing to the immune responses and environmental factors. Studies 
on hRSV viral loads revealed an association of higher level of hRSV with increased period of 
hospitalization, requirement of intensive care and respiratory failure in infants [35-37]. In 
addition, the host immune system also has a significant role in the hRSV disease severity. The 
components and balance of the host immune responses include the innate, cell-mediated and 
humoral immunity can result in different clinical manifestation of individuals infected with 
hRSV. Also, other factors that contribute to disease severity include immunocompromised 
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individuals [38, 39], immunomodulatory alterations associated Th1 and Th2 responses [40-43] 
and immune dysregulation [44, 45]. 
Once the hRSV virus enters the airways of the lung, its main viral target are respiratory 
epithelial cells with cell entry mediated through the attachment of G and F proteins. In response 
to the infection, the first line of defense to the virus are the host physical barriers and innate 
immunity. The respiratory tract mucociliary apparatus traps and removes pathogens and 
particulate matter from the airways. Furthermore, the respiratory mucosa produces surfactant 
proteins (SP), SP-A and SP-D, which enhances hRSV uptake by opsonization [46] and inhibits 
viral infection also through activation of macrophages [47]. Infection with hRSV triggers 
innate immune responses through binding of pattern recognition receptors (PRRs); TLR3, 
TLR4, TLR2, TLR7 and TLR9. Studies have shown that the double stranded RNA of hRSV 
can activate and upregulate TLR3 in lung epithelial cells and lung fibroblasts resulting in the 
activation of NK cells and several chemokines; CCL5 (RANTES), CXCL10 (IP-10) and 
CXCL8 (IL-8) [48, 49]. In addition, there are interactions between hRSV F proteins with TLR4 
and its accessory protein, CD14, in human monocytes [50]. This interaction triggers the signal 
transduction pathway through STAT and NF-κB resulting in transcription of various cytokines 
(e.g., GM-CSF, TNF-α, CCL2 (MCP-1), CCL3 (MIP-1α), etc.) and α and β interferons [51]. 
A few studies have also demonstrated hRSV interaction with TLR2 [52], intracellular TLR7 
and TLR9 [53], although the mechanisms of viral binding and downstream responses have not 
been thoroughly evaluated. Overall, the responses of the innate immune system not only 
protect the host against hRSV and provide time for adaptive immune development, but also 
establish the pathway of adaptive immune response and influence the disease outcome. 
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Various cellular components of the immune system respond to hRSV infection, and 
these include neutrophils, macrophages, eosinophils, dendritic cells, natural killer (NK) cells 
and lymphocytes. Neutrophils are recruited into the airway by cytokines and chemokines 
released from viral infected cells and are the predominant cell type associated with hRSV 
bronchiolitis [54-56]. The neutrophils induce damage and detachment of hRSV infected 
epithelial cells through degranulation and release of lytic enzymes [57]. The virus can infect 
or be opsonized by macrophage and monocytes which mediate antigen presentation and trigger 
inflammatory responses through the production various cytokines (e.g., proinflammatory 
cytokines (IL-6, TNF-α, IL-1β, GM-CSF, IL-16) and anti-inflammatory mediators (IL-10 and 
prostaglandin E (PGE)) [58]. Eosinophils are associated with bronchiolitis in hRSV infection 
and respond by degranulation and release of antiviral ribonucleases, such as eosinophil cationic 
protein and eosinophil-derived neurotoxin [59, 60]. These products may have positive effect 
on destroying the virus and infected cells, but also can contribute to pulmonary pathology [61]. 
Dendritic cells (DCs) contribute to defense by antigen presentation and cytokine release to 
stimulate and regulate the immune system response. Murine models of hRSV infection have 
demonstrated increases of both myeloid and plasmacytoid dendritic cells (pDCs) in the airways 
[62]. The pDC enhanced hRSV clearance suggesting an antiviral and protective role against 
hRSV [63] and increased myeloid DCs likely contribute to an inflammatory response during 
and after bronchiolitis [64]. NK cells and one of their main products, IFN-γ, are present at early 
stages of hRSV infection. Even though NK cells have important antiviral activity, few studies 
have characterized NK activity with hRSV infection and results are still inconclusive. Some 
studies have demonstrated higher NK cells and IFN-γ associated with less severe hRSV disease 
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in some individuals [65, 66], while other studies suggest NK cell involvement with acute lung 
injury in early RSV infection [67]. 
Infection by hRSV can stimulate the cell-mediated immune system through both CD8+ 
and CD4+ T lymphocytes by antigen presentation of DC in the draining lymph nodes. The 
stimulation of CD8+ effector T cells is critical for the hRSV viral clearance [68-70]. In contrast, 
studies have also identified immune responses with pathological effects by effector and 
memory CD8+ T cells in response to viral reinfection [69, 71]. The differentiation of CD4+ T 
cells into Th1 or Th2 cells depends on the cytokines released during the innate immune 
response with the main cytokine, IL-12, stimulating differentiation to Th1 and IL-4, IL-5 and 
IL-13 stimulating the differentiation to Th2.  
There is much evidence demonstrating a balance between Th1/Th2 responses that result 
in different pathological outcomes of the hRSV infection. Increased expression of Th2-type 
humoral response including IL-4, IL-5, IL-13 and IgE was seen in many studies of infants and 
children with severe hRSV infection [42, 72-74]. Furthermore, reduction in the Th1 effector 
cytokine, IFN-, and elevation of IL-4/IFN- ratio were demonstrated in cases of infants with 
acute bronchiolitis [42, 65]. Many investigators have tried to explain the cause of skewed Th2 
response with severe disease of hRSV infection. Some of the hypotheses include the host 
immune status and immune modulatory effect from certain viral components. Immune 
response of infants tends to have stronger Th2 response than Th1 [75, 76]. Certain amino acid 
domains of hRSV G glycoprotein are involved in Th2 biased response in many pathogenesis 
studies and vaccine testing with cell cultures and animal models [77-79]. The infection of 
hRSV with a Th2 biased response is also associated with the development of allergy, asthma 
and wheezing [80, 81]. 
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The humoral immune response is essential for protection of hRSV reinfection. Viral 
neutralizing antibodies are made against F and G proteins. Studies have shown detection of 
hRSV specific IgM, IgG, IgA in the serum and IgE and secreted IgA in the respiratory 
secretions of infant patients [82]. The first antibody response after infection, IgM, can be first 
detected around 5-10 days post infection and lasts as long as three months post infection. The 
peaked response of IgG is somewhat delayed for the first response to hRSV. The IgG titer 
reaches its peak around 20-30 days after the start of symptoms. The IgG response is produced 
faster and with higher magnitude upon the second exposure to the virus [83, 84]. IgA can be 
detected in both secreted and cell bound form in nasopharyngeal secretions. It is first present 
at 2 to 5 days after infection and peaks between 8-13 days after infection. Additionally, hRSV-
specific IgE has been detected in infected children. In children less than 6 months of age, only 
about 50% had an antibody response to hRSV [85, 86]. This is likely due to the presence of 
passive maternal antibody and the weak responses of the immune system [87]. In one study , 
three quarters of adults infected with hRSV displayed a 4-fold decrease in neutralizing anti-
hRSV IgG antibody one year after infection [88]. Thus, hRSV infection often produces a short 
duration of protective antibodies, which permits subsequent reinfection. Reinfections typically 
produce milder clinical symptoms in uncomplicated RSV upper respiratory tract infection [16, 
17]. 
 
Regulation of immune responses to hRSV 
Regulatory Foxp3+CD4+CD25+ T cells (Treg) have an important role in regulating the 
inflammatory responses to hRSV. A number of studies were performed in laboratory rodents 
that identified a role of Treg cells in limiting immunopathology during the hRSV infection. 
Increases of pro-inflammatory cytokines, including IFN- and TNF-, and number of CD8+ T 
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cells were associated with enhanced disease severity in Treg-depleted mice [89]. Another study 
suggested that Treg contributes to the resolution of hRSV by reducing eosinophilia and Th2 
response [41]. Modulation of B cell activity associated with Treg was seen in an hRSV-infected 
mice model, particularly through the decreased production of anti-F protein neutralizing 
antibody [90]. In cases of hRSV-infected hospitalized infants, there were reduced levels of 
circulating Treg and Foxp3+ mRNA for 3 weeks following acute infection [44, 91], although 
a different study did not show correlation between the number of Treg and disease severity 
[92]. Immunoregulatory cytokines such as IL-10 have also been demonstrated to have a role 
in the severity of hRSV infection. Higher expression of IL-10 regulate and inhibit the 
inflammatory response of mice infected with hRSV [93]. Certain single nucleotide 
polymorphisms of IL-10 gene also contribute to hRSV disease outcome [94]. 
 
Animal Models for hRSV and the Neonatal Lamb Model 
 Animal models for hRSV infection have been established for the purpose of studying 
the pathogenesis, immunological response and pharmaceutical testing with the objective of 
finding novel therapies and preventive measures [95, 96]. These include: 1) rodent models 
such as mice and cotton rats, 2) non-human primates (NHPs), such as rhesus macaques, 
baboons, and chimpanzees; 3) ruminants, such as cattle and neonatal lambs, and 4) ferrets. The 
ideal animal model would replicate key features of the disease in humans, including having 
similar anatomical structure, similar immunologic responses, clinical signs and respiratory 
tract lesions to hRSV infection. Nevertheless, many concerns and limitations are unavoidable 
with animal studies including animal husbandry, handling, housing, costs and ethical issues. 
Thus, understanding the strengths and weaknesses is crucial for constructing research 
experiments, performing laboratory tests and evaluation of the results of each animal study. 
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This section will briefly describe and update the advantages and disadvantages of animal 
models for hRSV with focus on the neonatal lamb model. Further details of other animal 
models had been reviewed elsewhere [95, 97, 98]. 
 Cotton rats (Sigmodon hispidus) have become a standard model for evaluation of 
preventive and therapeutics agents for hRSV [97, 99, 100]. Cotton rats are relatively small and 
hRSV has a moderate degree of permissive viral replication. Specialized training in handling 
cotton rats is needed due to excitability, agility and aggressiveness towards handling of this 
species. Limited molecular tools for cotton rats can be an issue for selecting this model for 
hRSV studies, but recently there are more available immunological reagents specific for cotton 
rats. Another rodent species for hRSV are mice [98, 101]. The laboratory mouse is an 
exemplary model for gene target studies due to the wide use of transgenic mice and implication 
of genetic knockouts in this species. In addition, experiments using the mouse model are easier 
to conduct due to the relatively small size of the animal, low costs, and extensive molecular 
tools and assays available. Nevertheless, conducting hRSV studies in mice comes with 
disadvantages including the high genetic, immunological and anatomical structural differences 
from humans as well as low replication of hRSV in mice. 
More closely related species to humans are non-human primates (NHPs). Even though 
these animal species have the most advantages in the similarity of genetic, anatomic, 
immunologic response to humans, the extensive husbandry care, ethical issues and expensive 
costs hinder the advancement of NHPs as model for hRSV. Studies of experimental hRSV 
infection have been performed in NHPs species including owl monkeys [102-104], baboons 
[105], cebus monkeys [106], African green monkeys [107, 108], bonnet monkeys [109-111], 
cynomolgus monkeys [112, 113], rhesus macaques [114-118], and most notably, the 
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chimpanzee. Chimpanzees are permissive to viral replication and develop clinical symptoms 
with hRSV infection [114, 119]. This model has been proven useful for vaccine studies [120, 
121]. 
 An experimental lamb model for hRSV infection was developed and this model has 
been more increasingly accepted in recent years. Lambs infected with hRSV mimic hRSV 
infection in human infants [122]. Lambs have similarities of lung development, structure, 
cellular components in airways, immunological responses, and bronchiolar lesions compared 
to human infants. The lamb lung undergoes prenatal alveologenesis as do human infants and 
there are also similarities in lung size, the airway branching pattern, the amount of submucosal 
glands in the airways and percentage of club cells (20-30%) to that of human infants  [122-
124]. The overall decrease of immune response including the pulmonary neutrophilic response 
to hRSV in the preterm lamb is similar to that of preterm infants. Other immunological factors 
that mimic the human includes the presence of dendritic cells (DCs) responses to hRSV [122], 
genetic expression of IL-8 (rodents lack IL-8 gene) [125-127], and presence of Duox/LPO 
system in the airways [128-130]. The lesions of hRSV-infected lamb are similar to human 
infection including necrotizing bronchiolitis, neutrophilic and lymphoplasmacytic infiltration 
with syncytial cell formation [131-135]. The viral antigen is present in bronchial and 
bronchiolar epithelial cells as well as infection in type II pneumocytes. Enhanced hRSV 
disease severity was demonstrated in preterm lambs compared to newborn lambs and in lambs 
vaccinated with formalin-inactivated hRSV vaccine [136]. Also, lambs are susceptible to at 
least three strains of hRSV (Memphis, A and Long strains) [122, 131] as well as bovine 
respiratory syncytial virus (bRSV) [137], ovine and human parainfluenza viruses [138].  Thus, 
the lamb model of hRSV infection can be used for modeling hRSV infection in newborn 
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infants, preterm infants, and also vaccine, therapeutic and potentially asthma studies. The 
ability to eliminate maternal passive immunity interference by use of colostrum-deprived 
lambs is another advantage of using this animal model. Lambs are easy to handle and restraint 
with large and accessible blood vessels for sampling or placement of an intravascular drug 
delivery system. The disadvantages of using lamb studies is finding the source of large-scale 
sheep breeding facilities to produce and customize the lamb for experimental use. A middle-
size to large housing facility is needed with lamb studies compared to rodents, though not as 
specialized and extensive as NHPs. Another concern with using sheep experimental model is 
the limited molecular tools and genomic data for this animal species which can be more 
difficult to perform certain experimental assays, although key types of information are routine 
and proteomics as well as genetic assays are readily available. 
 
Development of Vaccine and Therapeutic Agents for hRSV 
 Advancement in treatment, prevention and control methods is necessary for the fight 
against hRSV infection. For the past half a century, numerous studies have been designed to 
identify suitable vaccine and pharmaceutical agents for controlling hRSV infection. The 
development of vaccine and therapeutic agents of hRSV has been challenging for researchers 
and scientists, and competitive in the pharmaceutical world. Currently, there are no vaccines 
available for commercial use and commercially approved therapeutic agents are limited. The 
following section will give a brief review on the ongoing process and challenges of hRSV 




Vaccine development of hRSV 
History of RSV vaccine development 
The first human hRSV vaccine developed was a formalin-inactivated hRSV vaccine 
(FI-RSV) in the 1960s and the result was unsatisfactory. The vaccine did not protect against 
infection, but instead exacerbated the inflammation from subsequent hRSV infection in 
children [139]. The problem with vaccine-enhanced immunopathology of hRSV has led to 
many studies on and investigations of the virus, advanced techniques in hRSV vaccine 
development, and alternative tools for treatment and prevention. Several studies were 
conducted to answer why hRSV immunization caused vaccine-induced enhancement. Studies 
have suggested the mechanisms of this immunopathological outcome were from the production 
of hRSV non-neutralizing antibody [140, 141] and imbalance of Th1/Th2 responses associated 
with Th2 bias [80, 112, 142, 143], but the precise mechanism still remains unclear. Other than 
the formalin-inactivated vaccine, there are reports of other hRSV vaccine types resulting in the 
same vaccine-induced disease enhancement. Recombinant vaccinia virus (rVV) vaccine with 
expression of different hRSV proteins was tested in mice followed by challenge with hRSV. 
Results indicated that the rVV recombinant with G protein (rVV-G) induced eosinophilia and 
disease enhancement subsequent to viral challenge [144]. The route of inoculation is another 
factor in determining the disease enhancement. Inoculation of rVV-G intranasally or 
intraperitoneally appeared to induce protection against challenging with hRSV [145]. Host 
factors including age and genetic could additionally determining the post-vaccination outcome. 
There is evidence that the severity of symptoms is age dependent with younger children 
exhibiting more severe clinical signs [146, 147] and genetic predisposition to a Th2 response 
[148] is associated with vaccine-enhancement disease of hRSV. 
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Current RSV vaccine development strategies 
The current goal is to develop hRSV vaccine that exhibit protection against hRSV and 
lack adverse effects. Many attempts in designing different types of RSV vaccines were 
undertaken (e.g. subunit vaccine, vector vaccine, live attenuated vaccine, etc.), but none has 
been licensed for human usage due to many factors, most importantly the safety concern 
associated with infants and children.  
The subunit vaccines previously evaluated were based on the G and F proteins, the 
neutralization target. Newer vaccines are based on multivalent recombinant proteins and 
conformation change F protein epitope. As stated earlier, G protein could be integral in 
mediating the induction of vaccine-induced disease. Interestingly, studies have been made to 
pinpoint the G protein coding gene sequence site responsible for induction of pulmonary 
eosinophilia and disease enhancement [149]. With that in mind, a recombinant G protein 
fragment subunit vaccine was designed, and it had protection against hRSV challenge without 
inducing lung lesions in animal models [150-152]. However, this did not induce sufficient 
duration of protection from hRSV [153]. F subunit vaccines have been tested in many 
preclinical trials, some of which were safe and generated protection against hRSV challenge 
in children over the age of 1 year, adults and elderly [154-157]. Others have demonstrated 
evidence of same vaccine-enhanced immunopathology as those with FI-RSV. This may be 
associated with the formulated adjuvants in the vaccine [158, 159]. Studies of different 
conformation changes in F protein during cell attachment have led to a new candidate for F 
subunit vaccine. Results showed that pre-fusion F protein epitopes induces strong neutralizing 
antibody response [160]. The conformation metastability of the pre-fusion F protein compound 
that tends to spontaneously fold to the post-fusion F protein conformation is a challenge for 
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vaccine developers and biochemists [161, 162], and multiple studies were conducted and 
currently in pursuit to find the solution in stabilizing the protein construct and characterize the 
neutralizing epitopes [161, 163]. 
Intranasal immunization of live attenuated hRSV vaccines has shown no association 
with priming of disease enhancement [164]. Construction of live-attenuated hRSV vaccines 
are from two platforms; 1) attenuation of virus through viral cold passage or chemical 
mutagenesis [165, 166], 2) reverse genetically engineered virus [167]. Some recombinant live 
attenuated vaccines have advanced into phases of human and infant clinical trials with the aim 
to identify the level of attenuation to balance the effectiveness and the safety of the vaccine 
[167-170]. 
Combined application of subunit hRSV antigen with different Th1 promoting adjuvants 
was tested in order to overcome the vaccine-induced immunopathological enhancement from 
Th2 biased immune response. Monophosphoryl lipid A (MPL), QS21 or both, in combination 
with FG chimeric protein [171], single subunit protein [172] and even with FI-RSV, elicited 
better Th1-biased responses and reduced pulmonary inflammation. Addition of unmethylate 
CpG oligodeoxynucleotides (ODNs) to F protein subunit vaccine induces the production of 
IL-12 enhanced Th1 biased immune responses resulting in reduction of pulmonary 
eosinophilia and increased viral clearance efficacy from the lung of animal models [173, 174]. 
Administration of CpG prior to hRSV infection in neonate mice protected against disease 
enhancement [175]. When formulating CpG ODN with formalin-inactivated bovine 
respiratory syncytial virus (bRSV), this resulted in stimulation of high levels of antibody, IFN-
γ expression and viral clearance after bRSV challenge [176]. Currently, human clinical trials 
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of CpG-ODNs hRSV vaccine have not been initiated and little is known about the effect of the 
vaccine in human infants with maternal-derived antibody and deviation of antibody responses.  
The ISCOMS vaccine delivery system was also designed and tested for RSV surface 
protein with Th1 promoting adjuvant. The results were effective in both neonates and adult 
mice, including the development of good Th1/Th2 balance, high cell-mediated immune 
responses and protection from viral challenge, although there was evidence of pulmonary 
eosinophilia and a high level of IL-4 production in neonates [177]. To avoid the maternal 
antibody and stimulate the mucosal immune system, ISCOMS was also used for delivery of 
hRSV subunit mucosal vaccine. Other combination of adjuvants and hRSV antigens for 
mucosal administration includes FI-RSV with influenza virosomes and E. coli heat-labile toxin 
and fragment G subunit vaccine with cholera toxin B. Newer mucosal vaccine designs involve 
hRSV virosomes containing different Th1 promoting adjuvants (e.g., MPL, TLR2 and/or 
NOD-2 ligands) achieved protection against infection with hRSV without disease 
enhancement in animal models [178, 179]. 
Many vectored vaccines have been in trials for protection against hRSV. These have 
advantages to induce immune responses similar to that of natural infection and can produce 
antibodies against multiple pathogens. Additionally, adenovirus vectors are capable of 
inducing antibody even in the presence of maternal antibody. For hRSV, replicating vaccinia 
vector vaccines expressing hRSV proteins have been tested with little success due to safety 
concern of disease induced by the vector itself in infants and children [180-182]. More recent 
studies using a recombinant influenza virus vector vaccine with hRSV proteins protected 
against hRSV virus without priming of enhanced disease in mice and cotton rats [183]. Other 
vector hRSV vaccines tested were Sendai virus vector [184, 185], measles virus vector, 
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Newcastle disease virus vector with F protein [186] and modified Bacillus Calmette-Guerin 
(BCG) expressing multivalent RSV proteins [187]. 
Virus-like particles (VLPs) vaccines using different proteins have been developed. 
VLPs for hRSV were developed from an influenza virus matrix protein core with hRSV-F or 
G on the surface. The immunization of VLPs protected and reduced RSV viral load post 
challenge [188]. Mixed VLP of hRSV F and G proteins can provide high level of protection 
without vaccine-enhanced disease after hRSV infection. However, the use of VLP from G 
protein alone could cause vaccine-enhanced disease similar to FI-RSV [189]. More recently, 
smaller size VLP called nanoparticles, were designed from F protein and tested for efficiency. 
Purified hRSV F nanoparticles induces neutralizing serum antibodies and inhibition of viral 
replication in the lung without signs of disease enhancement in cotton mice [190]. Another 
nanoparticle vaccine used RSV G protein with CX3C chemokine motif induces similar results 
[191]. Additional tests were performed by immunizing animal models with combination of 
nanoparticles VLP of hRSV with DNA vaccine. These induced a significant Th1 immune 
response with high viral clearance, suggesting good potential as a hRSV vaccine candidate and 
further investigation on its effectiveness is warranted [192]. 
 
Therapeutic agents for prevention and treatment of hRSV 
 The general goal in developing hRSV therapeutic agents is to design compounds that 
inhibit viral entry into the respiratory epithelial cells and/or interfere with the viral replication. 
Two broad groups of therapeutic agents have been developed for hRSV; immunotherapy and 
small molecule inhibitor compound. Many of the hRSV therapeutics are in preclinical phase 
of development through in vitro testing and animal trials.  The most common target for these 
therapeutic compounds is the F protein that functions in viral fusion and entry into the 
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respiratory epithelium. Some anti-fusion protein antibodies and fusion protein inhibitors have 
advanced to human clinical phases with only a few licensed for commercial use. Other targets 
for hRSV therapies include inhibition of viral RNA polymerase, nucleocapsid mRNA and 
hRSV nucleoprotein (N).  
 
Immunotherapy against hRSV 
Immunotherapy and the implication of monoclonal antibodies as therapeutics have 
been used extensively in human medicine and the advancement in this area has led to novel 
production of monoclonal antibodies that can manipulate the outcome of many diseases and 
disorders. The only approved immunotherapeutic compound against hRSV is palivizumab 
(Synagis), a humanized monoclonal antibody against the F protein. It has shown to have good 
success in prophylactic treatment and was recommended for patients with higher risk of hRSV 
infection [193]. The mechanism of palivizumab is through the binding of viral F protein and 
neutralizing the virus, preventing it from entry into the host cells. Previous data indicated the 
use of palivizumab resulted in the reduction of hRSV-associated hospitalization rates by 55% 
in premature infants, when compared to a placebo [194]. Few studies have reported the use of 
palivizumab as an hRSV treatment [195]. However, due to the short half-life, the inconsistent 
effectiveness between individuals and the high cost, this treatment in no longer recommended 
for routine usage [196]. 
Other forms of F protein antibodies are currently in various phases of animal and 
clinical trials including polyclonal hRSV neutralizing antibody, RI-001 and RI-002 [197-199]; 
monoclonal antibody, REGN222 [200], MEDI8897 [201] and trimeric nanobody, ALX-0171 
[7, 202, 203]. The polyclonal antibody RI-001 and RI-002 are derived from plasma donors 
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with high hRSV titers. The use of RI-001 was tested on children and adults who underwent an 
organ transplant, but the efficacy was difficult to assess due to lack of a control group [198, 
199, 204]. REGN222 is a fully humanized monoclonal IgG1 antibody that specifically target 
viral F protein. MEDI8897 is a recombinant human IgG1k monoclonal antibody with modified 
Fc region that prolongs the antibody half-life. MEDI8897 acts by neutralizing the pre-fusion F 
protein and is intended for use in the prevention of hRSV infection. Trimeric nanobody ALX-
0171 is designed to bind and neutralized the antigenic site of the F protein. This compound can 
be delivered through an aerosol route with high treatment effectiveness in animal trials, 
including the lamb model [7], and has advanced to phases of clinical trials.  
 
Small molecule inhibitors of hRSV 
Currently treatment in most cases for hRSV consists largely of supportive care for the 
disease symptoms. The only FDA approved specific treatment for severe cases of hRSV is the 
broad-spectrum antiviral drug Ribavirin, a guanosine analog, which inhibits inosine-5’-
monophosphate dehydrogenase (IMPDH) resulting in reduced formation of mRNA and viral 
polymerase. This aerosolized drug has been used to treat hRSV infection, but the results still 
remain controversial due to the failure to have a significant therapeutic effect, high cost and 
the direct and indirect side effects [205]. Other drugs that inhibit the viral replication and 
assembly have been tested for hRSV with various outcomes. The largest group of hRSV small 
molecule inhibitors therapy are the fusion inhibitors. Numerous fusion inhibitors have been 
developed and some are currently in different phases of clinical trials, such as AK-0529 [206], 
Enzaplatovir (BTA-C585) [207], JNJ-53718678 [6, 208, 209], Presatovir (GS-5806) [210-
213], RV521 [214]. The general mechanism of fusion inhibitors is to prevent viral infection of 
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the host respiratory epithelial cells by targeting the F protein which facilitate viral entry and 
membrane fusion [215]. Thus, resulting in decreased viral load and pulmonary lesions. 
Another group of hRSV therapies are is the non-fusion protein inhibitors that are 
designed to target components other than viral fusion protein which are associated with viral 
entry and replication. Some non-fusion protein inhibitors have advanced into phases of clinical 
trials. Lumicitabine (ALS-008176) is a nucleoside analog that inhibits the viral RNA 
polymerase [216, 217]. RSV-604 is a compound benzodiazepine derivative that inhibits 
nucleocapsid (N) protein, which is a necessary component for viral replication [218, 219]. 
Small interfering RNA, ALN-RSV01, has also been developed to prevent the formation of 
nucleocapsid by targeting nucleocapsid mRNA. Interestingly, administration of ALN-RSV01 
reduced the risk of bronchiolitis obliterans development in hRSV-infected lung transplant 
patients in clinical trial [220]. There are a large number of hRSV therapeutics that are in 
preclinical phase of development through in vitro testing and animal trials that is beyond the 
scope of this review. Some of these compounds will be mentioned in greater details in 
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Abstract 
Human respiratory syncytial virus (hRSV) is a leading cause of respiratory infection in 
infants and children worldwide. It is crucial to explore new and effective treatment methods 
for hRSV. This study assessed the therapeutic efficacy of hRSV fusion protein inhibitor 
(hRSV-FPI) in a lamb model of RSV infection that has close similarities to hRSV infection in 
infants. A total of twenty-two, 1-3 days old lambs were divided into 5 groups; hRSV infected 
with administration of daily intragastric 1 mg/kg (T1) (n=4), 5 mg/kg (T5) (n=4) and 25 mg/kg 
(T25) (n=4) dosage of RSV-FPI for 5 consecutive days, hRSV infected with no treatment 
(n=5), and negative control (n=5). Clinical signs were recorded daily and at day 6 post-
infection, all lambs were euthanized and necropsied. In T5 and T25 treatment groups, lambs 
lacked clinical signs of RSV infection and hRSV lesions were not detected.  Focus-forming 
unit (FFU) assay did not detect viable virus in the lung tissue samples and low amount of virus 
was detected in BALF samples with 25 mg/ml dosage. No significant reduction of viable virus 
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was observed with 1 mg/kg dosage of RSV-FPI. Viral FFU level paralleled the amount of viral 
mRNA detected by RT-qPCR.  In summary, intragastric administration of hRSV-FPI at the 
appropriate dosage significantly reduced clinical signs, gross lung lesions and presence of 
hRSV in the lung tissue of lambs. This compound is a good candidate for future therapeutic 
usage for hRSV in infants and children. 
 
Introduction 
Human respiratory syncytial virus (hRSV) is a common cause of respiratory infection 
in infants and children worldwide. The virus causes respiratory symptoms including rhinitis, 
bronchiolitis, pneumonia and occasionally otitis media. The most common susceptible 
individuals are children younger than 5 years old and adults over the age of 65. Previous 
epidemiological data reported the disease causing hospitalization of approximately 160,000 to 
180,000 children under the age of 5 and an average of 177,000 hospitalized and 14,000 deaths 
in adults over the age of 65 each year in the United States [1]. The disease outcome can be 
more severe and fatal in children younger than 1 year of age [2]. Many research investigations 
have been made to find or develop prevention and treatment methods for hRSV and these range 
from vaccination to therapeutic antibody treatments and antiviral drugs. To date, there is no 
licensed vaccine for hRSV. Earlier vaccine development and usage of hRSV-formalin 
inactivated vaccine resulted in vaccine-enhancement immunopathology and death [3]. At 
present, only two therapeutic compounds are approved specifically for hRSV treatment which 
includes palivizumab, a humanized monoclonal antibody against F protein, and ribavirin, an 
antiviral guanosine analog. Previous data indicated that  the use of palivizumab resulted in the 
reduction of hRSV-associated hospitalization rates by 55% in premature infants, when 
comparing to placebo [4]. This compound is recommended as a prophylactic regimen for 
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patients with high risk of hRSV infection [5]. Few studies have reported the use of palivizumab 
as a hRSV treatment approach [6]. Ribavirin on the other hand is a broad-spectrum antiviral 
drug that inhibits inosine-5’-monophosphate dehydrogenase (IMPDH) resulting in reduced 
formation of mRNA and viral polymerase. The use of this aerosolized drug has been implicated 
for severe cases of hRSV infection, but the results still remain controversial due to the failure 
to have a significant therapeutic effect, its high cost and the direct and indirect side effects [7, 
8]. Treatment in most cases for hRSV remains mostly supportive.  
Attempts in finding alternative immunotherapy and antiviral compounds are crucial. 
Many candidates of anti-hRSV drugs are currently at different stages of development, 
preclinical tests and some in phases of clinical trials [9]. One of the most widely studied are 
hRSV small molecule fusion protein inhibitors (hRSV-FPI) that interact with the viral fusion 
protein and inhibits viral entry [10]. The process in development of the therapeutic compounds 
requires multiple efficacy and safety tests which involve laboratory experiments and trials in a 
hRSV-animal model such as cotton rats, ruminants, ferrets, non-human primates, and a 
recently established neonatal lamb model [11]. The hRSV-infected lamb model has similarities 
in lung anatomy, pulmonary immune response and pathology to human infants and represents 
an affective model for hRSV infection [12]. In this study, we evaluated the efficacy of an orally 
administered hRSV fusion protein inhibitor (hRSV-FPI) in a hRSV-lamb model. 
 
Materials and Methods 
Virus and Treatment Compound Preparations 
Human respiratory syncytial virus Memphis 37 strain (hRSV M37) was grown on HEp-
2 cell line and collected 48-72 hours after infection. The virus was extracted by freeze-thawing 
at -80°C followed by centrifugation (25,000 rpm, 10 min) to discard the cellular components. 
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The supernatant containing hRSV M37 was collected in 20% sucrose and stored at -80°C, by 
a procedure previously published by Grosz et al., 2014 [13]. The viral titer was evaluated using 
the standard focus-forming unit (FFU) assay.  
Fusion protein inhibitor, JNJ-53718678, was diluted in 20% acidified hydroxypropryl-
β- cyclodextrin (20 % HP-β-CD + HCl) at pH 2 (adjusted pH 7-7.4) to 6.25, 1.25 or 0.25 mg/ml 
prior to dosing and stored at room temperature. Administration of the compound was 
performed using gavage catheter with each dose washed down by 5 ml of 20 % HP-β-CD+HCl, 
pH 7-7.4. 
 
Animal Model and Experimental Design 
A total of 22, 1-3 day old colostrum-deprived lambs (Polypay, Suffolk and Dorsett 
crossbred) were randomly separated into 5 groups including hRSV infected lambs 
administered 3 different dosage of hRSV-FPI, JNJ-53718678, at 1) 25 mg/kg (T25) (n=4); 2) 
5 mg/kg (T5) (n=4); 3) 1 mg/ml (T1) (n=4); 4) hRSV infected given placebo vehicle (hRSV) 
(n=5); and 5) uninfected lambs (control) (n=5). Delivery of hRSV M37 was performed by 
nebulization at the concentration of 3.05 x 107 FFU/lamb in 7 ml cell culture media containing 
20% sucrose over a 30-minute period. Different concentrations of hRSV-FPI were given via 
intragastric administration each day for 5 consecutive days after hRSV infection. Intragastric 
administration using orogastric gavage of hRSV-FPI in 20% acidified hydroxypropyl-β-
cyclodextrin (HP-β-CD+HCl) solution was given at three different dosages (25, 5 and 1 mg/kg) 




Measurements of body weight, body temperature, respiratory rate, heart rate and 
antibiotic administration (ceftiofur sodium (Naxcel®)) were performed daily on all lambs. 
Plasma samples were collected at 24 hours prior to hRSV infection and 2, 24, 48, 72, 96, 120, 
144 hours after the first treatment dose. All animals were euthanized by sodium pentobarbital 
overdose on day 6 post-hRSV infection. Animal use and experimental procedures were 
approved by the Iowa State University’s IACUC committee (IACUC # 3-14-7748-0). 
 
Sample Collections and Necropsy 
Lung gross examination and scoring were performed by estimating the percentage 
affected and converted to a scoring scheme from 1 to 4 (0% = 0, 1-9% = 1, 10-39% = 2, 40-
69% = 3, 70-100% = 4). Bronchoalveolar lavage fluid (BALF) was collected from the right 
caudal lobe and right middle lung lobe using 5 ml, cold double-modified Iscove’s media 
(DMIM) (42.5% Iscove’s modified Dulbecco’s medium, 7.5% glycerol, 1% heat-inactivated 
fetal bovine serum, 49% Dulbecco’s modified eagle medium (DMEM) and 5 μg/ml kanamycin 
sulfate). For viral detection and pharmacokinetic analysis, lung tissue samples were collected 
from right cranial, left cranial, left middle and left caudal, frozen in liquid nitrogen and stored 
at -80°C until further processing. In addition, two pieces of lung tissue samples from right 
cranial, left cranial, left middle and left caudal lobes were placed in tissue cassettes and fixed 







 Quantification of JNJ-53718678 in plasma, lung and BALF 
 The plasma, lung and BALF samples were analyzed for JNJ-53718678 level by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The lower limit of quantifications 
were 2.5 ng/ml for plasma and BALF and 12.5 ng/g for lung samples.  
 
Histopathology and immunohistochemistry (IHC) 
Tissue cassettes containing lung samples were processed by the Histopathology 
Laboratory, Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State 
University for hematoxylin and eosin (H&E) stained slides, and unstained slides for 
immunohistochemical detection of hRSV antigen. For immunohistochemistry, the slide 
sections were placed in a heated oven (58C) and directly immersed in xylene for 
deparaffinization process. The slides were then rehydrated through a series of graded alcohols 
(100%, 95%, 70% methanol) with initial endogenous peroxidase blocking (3% hydrogen 
peroxide in methanol solution) then placed in double distilled water (ddH2O). Antigen retrieval 
was performed by placing the slides in pH 9.0 10 mM TRIZMA Base, 1 mM EDTA buffer and 
0.05% Tween 20 and heated to 125°C using a pressure-cooking device (Decloaking Chamber 
Plus, Biocare Medical, Concord, CA, USA). Subsequent steps of IHC staining were performed 
using a programmable automated IHC machine (BioGenex OptiMax i6000 staining system, 
USA). The protocol consisted of serum blocking with 3% bovine serum albumin (BSA) in 
TRIS-buffered saline with 0.05% Tween (TBST), followed by 20% normal swine serum (NSS) 
in TBST for 15 minutes each. The slides were then incubated with primary antibody for 90 
minutes (1:500 polyclonal goat anti-RSV antibody (Millipore/Chemicon, Darmstadt, 
Germany) in 10% NSS, 3% BSA in TBST solution. Subsequently, the slides were washed 
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twice with PBST then incubated for 45 minutes with 1:300 dilution of biotinylated rabbit anti-
goat IgG antibody in 10% NSS, 3% BSA in TBST solution. Secondary peroxidase blocking 
was performed by incubating the tissue sections in 3% H2O2 in TBST for 25 minutes followed 
by two TBST washes. Slides were then incubated in 1:200 streptavidin-horse radish peroxidase 
diluted in TBST for 30 minutes and washed 3 times with TBST. The slides were taken out of 
the machine and manually stained with chromogen substrate (Nova Red staining solution) for 
60-90 seconds and the reactions were stopped with ddH2O. After chromogenic development, 
the slides were counterstained with Shandon’s hematoxylin and mounted under cover-slipped. 
Lung histopathological scores were determined with H&E stained lung tissue sections. 
The scores ranged from 0 to 4 from lowest to highest pathological changes. Criteria for scoring 
include; lung consolidation, bronchitis, syncytial formation, bronchial and bronchiolar 
epithelial necrosis, bronchial and bronchiolar epithelial hyperplasia, presence of neutrophilic 
infiltration, perivascular and peribronchiolar lymphocytic infiltrates (Supplementary Table 1). 
Number of bronchioles and alveoli with hRSV signal were counted in a total of 20 fields at 
200X magnification with 22mm objective field from IHC slides of right cranial, left cranial, 
left middle and left caudal lung lobes. Semi-quantitative scores from 0-4 were assigned based 
on the number of positive signals observed in the bronchioles or alveoli (e.g. score 1=1-10 
positive counts, score 2=11-39 positive counts, score 3=40-99 positive counts and score 






Focus forming unit (FFU) on bronchioalveolar lavage fluid (BALF) and lung 
tissue 
Bronchioalveolar lavage fluid (BALF) and lung tissue samples were processed 
immediately after sample collection to detect viable virus using an infectious focus-forming 
unit assay (FFU). Prior to performing the assay, BALF samples were centrifuged at 15,600 x 
g. The supernatants were collected and spun through a spin column filter (Coster SPIN-X filter, 
Fisher Scientific, Hanover Park, IL, USA). In addition, lung tissue samples from right cranial, 
accessory, left cranial, left middle and left caudal (0.1 g each lobe, total of 0.5 g) were pooled 
and homogenized in 5 ml DMIM. Homogenized lung tissues were then centrifuged at 15,600 
x g to remove large debris and supernatants were collected. Each lung sample supernatant was 
centrifuged 2-3 times through a spin column filter. The filtrates of BALF and homogenized 
lungs were collected and used in the FFU assay. 
HEp-2 cells were grown in 12-well cell culture plates to 70-80% confluency in culture 
media (DMEM, 10% FBS, 50 μg/ml kanamycin sulfate). The BALF samples were tested at 
full strength and 10-1, 10-2, 10-3, 10-4 concentrations achieved by 10-fold dilution of the BALF 
samples in culture media. The media of the readily grown HEp-2 cells in 12-well cell culture 
plates was removed and 200 μl of each sample concentration was pipetted into duplicate wells 
and incubated at 37°C, 5% CO2 incubating chamber for 90 minutes. After sample incubation, 
1 ml of culture media was added to each well and the plates were allowed to further incubate 
for 48 hours at 37°C, 5% CO2. To start the staining process, the media was removed, and the 
cells were fixed in 60% acetone/40% methanol solution for 1 minute. The fixing solution was 
removed, and the plates were air-dried for 2 minutes before rehydrating with 1 ml/well TBST 
for 1 minute. TBST was removed and 1 ml blocking solution (3% BSA in TBST) was added 
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to each well and incubated for 30 minutes at room temperature. The blocking solution was 
removed, and primary polyclonal goat anti-RSV diluted to 1:800 with 3% BSA in TBST was 
added (325 μl/well) and incubated at 4°C, overnight with gentle rocking. All wells were 
washed 3 times with TBST and 1:800-diluted secondary fluorescence-tagged rabbit anti-goat 
IgG secondary antibody in TBST with 3% BSA was added to each well (325 μl/well). After a 
30 minutes incubation at room temperature, the plates were washed three times with TBST and 
1 ml of TBST was left in each well to prevent from drying. Each plate was observed under a 
fluorescence light microscope to count the infectious viral focus-forming colonies by 
averaging the result from the duplicated wells and calculating the FFU per ml.  
 
Real-time reverse transcription polymerase chain reaction (RT-qPCR) 
Lung tissue samples for RNA extraction were pooled from right cranial, left cranial, 
left middle and left caudal lung lobes (0.3 g each lobe) and homogenizing each 1.2 g pooled 
tissue amount for approximately 1 minute in 12 ml TRIzol solution (Invitrogen/Life 
Technologies, Carlsbad, CA, USA). A volume of 1.1 ml of each sample homogenate was taken 
for RNA extraction by adding 120 μl of chloroform and centrifuging at 12,000 x g, 4°C. After 
centrifugation, 550 μl of the upper aqueous layer was collected from each sample and mixed 
with 500 μl of isopropanol and allowed to sit for 10 minutes. The precipitated RNA was 
pelleted by centrifuging the samples for 10 minutes at 12,000 x g, 4°C. The RNA pellets were 
washed with 75% nuclease-free ethanol, centrifuged for 5 minutes at 16,000 x g, 4°C, allowed 
to air-dry for 35 minutes, then resuspended in 170 μl nuclease-free water and heated for 90 
seconds at 60°C. Subsequent to heating, 70 μl of each RNA extracted sample was treated with 
DNase (TURBO-DNase, Ambion, Austin, TX, USA) after which 80 μl of the samples were 
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diluted 1:10 with 710 μl of nuclease-free water and 10 μl of RNaseOUT (Invitrogen/Life 
Technologies, Carlsbad, CA, USA). RNA quantity and purity were assessed by 
spectrophotometry at wavelengths of 260 nm and 280 nm. 
At necropsy, 100 μl of BALF samples were stored at -80°C in 1 ml TRIzol solution 
until RNA isolation. The process of RNA isolation for BALF samples was performed 
according to TRIzol procedure (Invitrogen/Life Technologies, Clarlsbad, CA, USA). The 
resulting RNA from each BALF sample was resuspended in 100 μl nuclease-free water 
resuspended in 100 μl of nuclease-free water (Invitrogen/Life Technologies, Carlsbad, CA, 
USA) and incubated at 60°C for 2 minutes. The final RNA isolates were then diluted 1:10 with 
710 μl of nuclease-free water and 10 μl of RNaseOUT (Invitrogen/Life Technologies, 
Carlsbad, CA, USA). 
To quantify the amount of RSV viral particles, RT-qPCR was performed by targeting 
the nucleoprotein (N) mRNA of M37 RSV in each of the lung tissue and BALF RNA sample 
isolates. The primers and probe for the RSV M37 nucleoprotein (N) mRNA sequence in this 
study were designed using ABI Primer Express 2.0 based on RSV accession number M74568 
(Supplementary Table 2). Expression of cytokine and chemokine mRNAs were evaluated 
including IFN-λ, IL-13, CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES), CXCL10 (IP10), 
CD274 (PD-L1) and CC10 with primer and probe sequences of all targets listed in 
(Supplementary Table 2). RT-qPCR was performed using One-Step Fast qRT-PCR Kit master 
mix (Quantabio, Gaithersburg, MD, USA) in a Gene Amp 5700 Sequence Detection System 
(Applied Biosystems, Carlsbad, CA, USA). A serial dilution of a mixture of samples (Stock I) 
was used to create the standard curve for each mRNA target,  and all sample, standard and 
reagent dilutions were calculated and managed using PREXCEL-Q software [14]. Each sample 
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was duplicated and placed in the thermocycler for one round of pre-treatment (3 minutes at 
50°C, then 30 seconds at 95°C) followed by 45 cycles of 3 seconds, 95°C and 30 seconds at 
60°C. The virus copy number was calculated based on the standard curves generated from 
plasmid constructs. The relative quantity (rQ) of cytokine/chemokine and CD274 and CC10 
mRNA expression were calculated using the following equation: rQ = 10[(Cq − b)/m] where Cq 
represents the quantification cycle, b is the y-intercept and m is the slope of the standard curve 
generated for each target from serial dilutions of  Stock I [8]. 
 
Results 
Compound Level in Plasma, BALF and Lung Tissue 
Plasma concentration of JNJ-53718678 was measured daily once the compound was 
given with additional evaluation in the BALF and lung tissue (day 6) (Fig 1). Results showed 
in the initial dosage of the compound collected at 26 hpi, the concentrations were highest in 
the T25 group (539.48 ng/ml), followed by T5 (229.67 ng/ml) and were the lowest in T1 (20.06 
ng/ml). The Ctrough plasma concentration of the drug increases and stabilized after the second 
dosage point evaluated at 48 hpi with levels of  3208.5, 105.0, and 6.13 ng/ml, respectively 
from high to low dosage group. The lung/BALF to plasma ratio was evaluated to determine 
the distribution of compound to the target organ. The ratio of lung/plasma (T25=8.76, T5=9.98, 
and T1=11.08) was higher than BALF/plasma ratio (T25=0.14, T5=0.08 and T1=0.57). 
 
Lung Pathology and Immunohistochemical Detection of hRSV 
Lambs administered the 25 mg/kg dose (T25) lacked macroscopic hRSV-associated 
lung lesions and the average percentages of hRSV affected lung involvement in the T5 and T1 
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groups were 1.43% and 35.95%, respectively (Fig 2). Bronchiolitis, syncytial cell formation 
and epithelial necrosis were undetectable in all treatment groups with none of other criteria 
detected for high treatment dose. Semi-quantitative evaluation of hRSV antigen localization 
with IHC staining scores were only detected in the low dose group (0.250.125 in the 
bronchioles and 0.330.31 in the alveoli). The average IHC scores of the hRSV infected group 
receiving no treatment were 1.830.26 in the bronchiolar and 2.460.44 in the alveoli (Fig 3, 
4). 
Clinical signs related to hRSV (e.g. wheezing and coughing) were not observed 
throughout the study. At day 3 pi, the body temperature increased slightly higher in the RSV 
inoculate groups. The respiratory rate and the heart rate were higher than normal range in all 
groups (normal respiratory rate in sheep = 20-40 breaths per minute, normal heart rate in sheep 
= 80-130 beats per minute) likely related to stress induced from restraining. All groups had 
similar trend of increasing body weight. 
 
Viral Titer and Viral RNA detection 
The viral titers and levels of viral RNA detected in each treatment groups were 
tabulated (Fig 5). Detection of viable virus in the lung and BALF at 6 dpi with FFU assay 
demonstrated a reduction of virus in a dose-dependent manner with the lowest average viral 
titers in the high dose group (T25) (BALF=2.50 FFU/ml, lung=0.00 FFU/g), moderate titers 
in the medium dose group (T5) (BALF=3.34x102 FFU/ml, lung=1.28x102 FFU/g) and the 
highest viral titers in the low dose group (T1) (4.38x104 FFU/ml, lung=2.24x105 FFU/g). 
Similar dose-dependent trend was observed with quantification of virions by RT-qPCR in the 
lung and BALF. The average level of virion copies in BALF and lung of the T25 were 5.99x106 
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copies/ml and 7.75x103 copies/g, T5 were 1.60x107 copies/ml and 2.78x104 copies/g, and T1 
were 1.31x108 copies/ml and 4.22x105 copies/g. There was a significant reduction of BALF 
and lung viral titer (p<0.001) and viral RNA (BALF = p<0.05 and lung = p<0.01) at >16 fold 
with the T25. Significant reduction of BALF and lung viral titer (p<0.01) and lung viral RNA 
(p<0.05) were also detected in T5 group. No hRSV virus was detected with FFU and RT-qPCR 
in the negative control group. 
 
Cytokine and Chemokines mRNA Expression 
Evaluation of cytokine and chemokine mRNA expression demonstrated an increasing 
trend of CXCL10 (IP10), CCL3 (MCP-1α), CD274 (PD-L1) and IFN- λ corresponding with 
higher viral load. However, there were no significant differences in measured cytokine and 
chemokine levels between hRSV infected and treatment groups when compared to the non-
infected group with a one-way ANOVA (Fig 6). 
 
Discussion 
Neonatal HRSV-Infected Lamb Model, a Model for Human Infants with HRSV Infection 
 Many animal models have been used to study the efficacy of vaccines, various 
therapeutics agents, and the pathogenesis of hRSV infection. Rodents represent the most 
widely used model of hRSV infection, with numerous studies using cotton rats [15, 16] and 
laboratory mice [17, 18]. These rodent models are useful for studying the pathogenesis and 
immunological response of hRSV infection. Some concerns with using rodent species as a 
human model are the differences in lung anatomical structure, lack of certain immunologic 
components such as interleukin-8 (IL-8) and variation of hRSV infection permissiveness 
compared to typical hRSV infection in human. Non-human primates (NHPs) have close 
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similarity with humans and are an ideal animal model for pathogenesis, vaccine testing and 
antiviral therapeutic studies [19-24]. The use of NHPs requires specialized facilities and some 
regulatory requirements. HRSV-infection in the neonatal lamb has many advantages for 
modeling hRSV infection in human infants because of the close similarities in pulmonary 
anatomy, immune response and viral induced lung pathology [12]. The tracheobronchial tree 
of sheep is characterized by irregular dichotomous branching similar to humans and large 
mammals. This feature can impact the deposition of aerosolized compound administration. The 
character of the immune response to hRSV infection is an important part of hRSV 
pathogenesis. The IL-8 gene is absent in rats and mice [25] and this cytokine plays a significant 
role in the recruitment of neutrophilic response to hRSV infection in humans [26, 27]. The 
expression of IL-8 gene is present in sheep and many other mammals [28]. The lung lesions of 
hRSV inoculation through nebulization are characterized by necrotizing and neutrophilic 
bronchiolitis, lymphoplasmacytic adventitial infiltrates and occasional syncytial cell formation 
with hRSV antigen localization in bronchiolar epithelium and occasionally in type II 
pneumocyte, with peak lesion development at 6 dpi [29]. In this study and others we have 
completed, we were able to replicate and establish similar hRSV lesions in infected lambs and 
also demonstrated differences in lesions and levels of virus at different dose of small molecule 
fusion protein inhibitor. Other studies of therapeutic compound testing with the hRSV-infected 
neonatal lamb model include administration of VEGF [30], CC10 [31], iodide administration 
[32] and immunotherapeutic compound, ALX-0171 [33]. Furthermore, vaccination studies 
with formalin-inactivated hRSV has been tested in this lamb model and demonstrated disease 
enhancement with subsequent hRSV infection [34]. Thus, the neonatal hRSV-infected lamb 
 56 
model remains as a suitable option for preclinical therapeutic and vaccine testing of hRSV 
infection, especially for representing human infants. 
 
Fusion Protein as Therapeutic Target for Small Molecule Inhibitor of HRSV 
Entry of hRSV into host cells is facilitated by attachment of G and F protein to cellular 
receptors including annexin II [35], CX3CR1 [36], nucleolin [37] and heparan sulfate 
proteoglycans [38]. These viral proteins and receptors are potential targets for novel 
therapeutics for hRSV with the most studied therapeutic target being the viral F protein. The 
use of a high throughput screening assay for compounds that inhibit hRSV F protein has led to 
the identification of many small-molecule inhibitors targeting hRSV F protein. Blockage of F 
protein using specific inhibitors such as CL-309623 and RFI-641 has been shown to prevent 
entry and fusion of the virus in vitro [39, 40]. JNJ-53718678, a recently discovered hRSV-FPI, 
binds and stabilizes the metastable prefusion conformation of hRSV F protein at the central 
cavity of the F protein trimer, thus preventing viral entry and attachment [41]. A similar 
mechanism was reported in other small-molecule F protein inhibitors including GS-5806 [42-
45]. Other mechanisms of F protein inhibitors involve blocking the binding of the F protein by 
creating a hydrophobic environment [40] and interacting with the HRA domain of the F protein 
(MDT-637, BMS-433771) [46, 47]. A recent study has suggested that there is a common 
binding site of these compounds at the pocket inside the trimeric ectodomain of the prefusion 
F protein [10]. The administration of these compounds has shown to inhibit hRSV replication 




Orally Administered Fusion Protein Inhibitor, JNJ-53718678, Reduced the Viral Load 
and Lung Lesions in a Dose-Dependent Manner in HRSV-Infected Lambs 
Evaluation of effective small molecule inhibitors includes compound efficacy, 
inhibitor-resistance mutation of the F protein, tolerability and safety of the compound, 
appropriate delivery route, half-life of the compound in tissue and pharmacokinetic 
distribution. The oral regimen of JNJ-53718678 diluted in 20% HP-β-CD+HCl, pH 7-7.4 given 
to the neonatal lamb model at up to 25 mg/kg did not appear to cause any clinical side-effects 
in the 6-day period of administration. When administered at a level of 25 mg/kg given 1 day 
post infection, plasma levels appeared to increase and stabilize by the time of the second daily 
oral dose (48 hpi), which overlaps with the 24-72 day post-infection progressive period of 
increase viral load in the neonatal lamb model infected with hRSV M37 [29]. The compound 
concentration in the lung was higher than in BALF at day 6 with a high compound lung/plasma 
ratio indicating good distribution of the compound to the target organ. The pulmonary viral 
load and lung lesions were reduced in a dose-dependent manner with a significant reduction of 
the viral titer and viral RNA at 25 and 5 mg/kg dosage level (Fig 5). Viral mRNA was present 
in the lung at the high dosage level, but lack of viral focus forming units indicates a lack of 
replicating and/or viable virions. This can be due to the compound ability to bind and neutralize 
the infectious virions similar to previously tested in vitro experiments [10, 41]. However, we 
could not rule out the carry over-effect of the inhibitor compound in the viral plaque assay 






The use of a neonatal lamb model of hRSV-infection is an appropriate option for 
preclinical testing of therapeutic compounds and vaccines for hRSV. Evaluation of the orally 
administered small molecule F protein inhibitor, JNJ-53718678, at the appropriate dosage in 
hRSV-infected lamb model demonstrated significantly reduced lung lesions, and a decreased 
amount of viable virus and viral particles. This potent antiviral compound is a suitable 
candidate for hRSV therapy with good potential for further clinical evaluation. 
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Figure 1: Plasma compound levels of JNJ-53718678  
The level of compound in plasma of 25 mg/kg (T25), 5 mg/kg (T5) and 1 mg/kg (T1) treatment 







































Figure 2: Morphological changes of lungs and average gross hRSV-associated lung lesion 
The figures represent the gross changes in the non-treated vehicle group, treatment groups administered 25, 5, 1 mg/kg of JNJ-












Figure 3: Microscopic lung lesions in hRSV-infected lambs and average microscopic 
consolidation score 
 
Marked to moderate neutrophilic and necrotizing bronchiolitis with syncytial cell formation 
and lymphoplasmacytic peribronchiolar cuffs were presented in the non-treated hRSV-infected 
lambs (3a, 3b). There is lack of inflammatory changes in the bronchioles of 25 mg/kg treatment 
of fusion inhibitor (T25) (3c). Mild neutrophilic inflammation and lymphoplamacytic 















































Figure 4: Immunohistochemical detection of hRSV antigen and immunoreactivity score  
 
Immunohistochemical staining of hRSV antigen was detected in sloughed/intact bronchiolar 
epithelial cells, pulmonary alveolar macrophages and type II pneumocytes in hRSV-infected 
vehicle group (4a). Lack of antigen detection were presented in 25 mg/kg (T25) (4b) and 5 
mg/kg treatment groups (T5) (4c) and hRSV antigen were detected at less amount in 1 mg/kg 





Figure 5: Viral titer detected in focus forming unit and RT-qPCR 
 
Level of viral titer detected by FFU (top) and viral RNA detected by RT-qPCR (bottom) in 
different treatment groups. Statistical analysis was performed by one-way ANOVA followed 
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Figure 6: Cytokines and chemokines mRNA expression (IP-10, MCP-1, MIP-1α, PD-L1, IFN, RANTES and IL-13) 
 
Graphs represent individual data points and geometric mean values (horizontal bar) of each treatment and the non-treatment group. 
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Abstract 
Background: The purpose of this study was to evaluate the therapeutic efficacy of a 
non-fusion replication inhibitor (JNJ-64166037) against human respiratory syncytial virus 
(hRSV) in a lamb model of human respiratory syncytial virus (hRSV) infection that mimics 
hRSV in newborn infants. In contrast to semi-permissive models, hRSV replicates to a high 
extent in lambs and causes lung pathology that is similar to lesions that develop in human 
pediatric populations. 
Methods: Neonatal lambs (1-3 days of age) were infected with the clinical isolate 
hRSV Memphis 37 via nebulization. Infected lambs were treated orally with JNJ-64166037 1 
hour after virus inoculation then once daily 24 hours after the first treatment with three different 
doses (2, 10 and 50 mg/kg). Clinical signs were recorded daily, and lambs were euthanized 
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day 6 post-infection. Virus titers in the lung and bronchoalveolar lavages were measured by a 
focus forming unit (FFU) assay and viral mRNA in lung and BALF were measured by RT-
qPCR. Macroscopic and microscopic lung lesions were scored, and viral distributions were 
determined by immunohistochemistry and RNA in situ hybridization. 
Results: JNJ-64166037 plasma levels remained above the protein-adjusted EC90 at the 
highest tested dose (50 mg/kg) with a lung-to-plasma ratio of 0.7 indicating that the compound 
was distributed to the infected lung. A dose-dependent antiviral effect was associated with a 
potent reduction (>100 fold) of detectable lung infectious virions at 50 mg/kg. In addition, the 
amount of hRSV RNA correlated the pronounced decrease in infectious virions. Similar 
observations were seen in bronchioalveolar lavages. Consistently, the amount of virus detected 
in the lung of the lambs treated with 50 mg/kg was significantly lower than with lower dose 
treatments. Lungs of lambs receiving the 50 mg/kg dose lacked macroscopic and microscopic 
lesions. 
Conclusion: Oral administration of the non-fusion replication inhibitor JNJ-64166037 
at appropriate dose has potent antiviral effects in the lamb model of RSV infection in a dose-
dependent manner. This mode of therapeutic intervention eliminated the hRSV-induced lung 
lesions assessed in the model. JNJ-64166037 might offer new opportunities for RSV 
bronchiolitis treatment in infants and children. 
 
Introduction 
Human respiratory syncytial virus (hRSV) is a leading cause of viral respiratory tract 
infection in infants and children worldwide manifesting in bronchiolitis and pneumonia. 
Severe hRSV infection have been reported in preterm infants and children younger than 1 year 
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of age resulting in hospitalization and death in certain cases [1]. The virus can also cause 
detrimental disease in older individuals  of more than 65 years of age [2]. 
Development of effective vaccines and therapeutic compounds is essential for 
prevention and treatment of hRSV infection. A formalin-inactivated hRSV vaccine used in 
human infants was unsatisfactory, resulting in vaccine-induced disease enhancement with 
subsequent hRSV infection [3]. Alternatively, therapeutic and prophylactic compounds that 
inhibit viral entry and interfere with viral replication by targeting viral fusion (F) protein and 
machinery required for viral replication, such as viral RNA polymerase, nucleocapsid mRNA, 
hRSV nucleoprotein and viral G protein, have been studied and developed for precise, 
mechanistic, molecular therapies [4]. Such compounds require extensive laboratory testing, 
animal trials in the preclinical stage, and multiple phases of clinical trials in humans. An animal 
model for hRSV infection in infants has been established in newborn lambs in order to study 
the pathogenesis and response to many types of prophylaxis and treatments [5]. In contrast to 
semi-permissive hRSV replication in some animal models, hRSV replicates to a high extent in 
lambs and causes lung pathology that is similar to lesions observed in human pediatric 
populations [6]. The objective of this study was to evaluate the efficacy of hRSV replication 
inhibitor (JNJ-64166037), for the therapeutic treatment of hRSV by experimental trial on 
hRSV infected neonatal lamb model of hRSV infection in infants. 
 
Materials and Methods 
Animal Model and Experimental Design 
Colostrum-deprived lambs, 1-3 days of age, were infected with clinical isolate of hRSV 
Memphis 37 via nebulization of 6 ml viral solution to achieve the final viral inoculant amount 
of 3.5 x 107 FFU/lamb. Infected lambs were treated orally 1 hour after virus inoculation then 
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once daily 24 hours after the first treatment with different doses of antiviral replication 
inhibitor compound JNJ-64166037 (i.e., 2 mg/kg (T2, n=5), 10 mg/kg (T10, n=5), and 50 
mg/kg (T50, n=5)). Positive hRSV infected control lambs (RSV, n=6) were given 20% 
acidified hydroxypropryl-β- cyclodextrin (20 % HP-β-CD + HCl) treatment vehicle. Mock 
infection with pure culture media was administered in the negative control group (control, 
n=5).  
Measurements of body weight, body temperature, respiratory rate, and heart rate were 
performed daily on all lambs. Each animal received daily prophylactic antibiotic treatment 
(ceftiofur sodium, Naxcel®). Plasma samples were collected sequentially to determine the 
kinetics of compound in circulation at pre-dose, 2h after the first and last dose, and at 24h 
following each dose up to 144h. The animals were later euthanized with sodium pentobarbital 
at day 6 post-infection to collect bronchoalveolar lavage fluid (BALF) and lung samples for 
further virus quantification and tissue analysis. BALFs were collected from the right caudal 
lobe and right middle lung lobe of each lamb using 5 ml, cold double-modified Iscove’s media 
(DMIM) (42.5% Iscove’s modified Dulbecco’s medium, 7.5% glycerol, 1% heat-inactivated 
fetal bovine serum, 49% Dulbecco’s modified eagle medium (DMEM) and 5 μg/ml kanamycin 
sulfate). For viral detection and pharmacokinetic analysis, lung tissue samples were collected 
from right cranial, left cranial, left middle and left caudal lobes, frozen in liquid nitrogen and 
stored at -80°C until further processing. In addition, lung tissue samples from right cranial, left 
cranial, left middle and left caudal lobes were placed in tissue cassettes and fixed in 10% 
neutral-buffered formalin for histopathological, immunohistochemical staining and RNA in 
situ hybridization. Animal use and experimental procedures were approved by IACUC and 
IBC at Iowa State University (IACUC# 3-14-7748-0, IBC# 01-D/I-0008-A/H). 
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Viral Stock Preparation and Nebulization 
Human respiratory syncytial virus Memphis 37 strain (hRSV M37) was grown on HEp-
2 cell line with Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine 
serum (FBS) and 50 g/ml kanamycin sulfate. Once the viral growth achieved more than 90% 
cytopathic effect, the virus was extracted by freeze-thawing process of viral infected cells. 
Clarification process was performed by centrifugation at 5,000 x g for 10 mins. The 
supernatant was diluted with 20% sucrose then stored at -80°C [7]. A small sample of the stock 
virus were collected to determine the viral titer through a viral plaques assay. The virus stock 
was then diluted into 6 ml of culture media to the concentration of 2.5 x 107 FFU/ml needed to 
achieve appropriate final dose administration of 3.5 x 107 FFU/lamb. PARI LC SprintTM 
nebulizers were used to administer 6 ml of the diluted virus to T50, T10, T2 and RSV groups, 
and delivered pure culture media to the mock-infected negative control group. 
 
Replication Inhibitor Formulation, Administration and Quantification 
The hRSV replication inhibitor, JNJ-64166037, was dissolved in 20% acidified 
hydroxypropryl-β- cyclodextrin (20 % HP-β-CD + HCl) at pH 7.4 to 12.5, 2.5, or 0.5 mg/ml 
concentrations and stored at 4C prior to compound delivery. An appropriate amount of the 
compound for each treatment group (2, 10 and 50 mg/kg) was orally administered to the lambs 
through gavage catheter then followed by 5 ml of 20 % HP-β-CD+HCl, pH 7-7.4 to wash down 
any compound residues. The plasma, lung and BALF samples were analyzed for JNJ-
64166037 levels by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The 
lower limit of quantifications was 2.5 ng/ml for plasma and BALF and 12.5 ng/g for lung 
samples.  
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Focus Forming Unit (FFU) on BALF and lung tissue 
The focus forming unit (FFU) assay was conducted on the BALF and lung tissue 
samples to evaluate the hRSV viral titers. Prior to performing the FFU assay, BALF samples 
were clarified by centrifugation at 15,600 x g. The supernatants were collected and spun 
through spin column filters (Coster SPIN-X filter, Fisher Scientific, Hanover Park, IL, USA). 
A similar clarification process was performed with lung tissue samples by pooling and 
homogenizing the right cranial, accessory, left cranial, left middle and left caudals (0.1 g each 
lobe, total of 0.5 g) in 5 ml DMEM. Homogenized lung tissues were then centrifuged at 15,600 
x g to remove cellular debris and the supernatants were collected. Each lung supernatant was 
centrifuged 2-3 times through spin column filters. The filtrates of BALF and homogenized 
lung were collected for further evaluation with the FFU assay. 
HEp-2 cells were grown in 12-well cell culture plates to 70-80% confluency with 
DMEM culture media containing 10% FBS and 50 μg/ml kanamycin sulfate prior to adding 
the samples. The BALF and lung samples were tested at full strength and 10-1, 10-2, 10-3, 10-4 
concentrations achieved by 10-fold dilution of the samples with culture media. The media was 
removed from the HEp-2 12-well cell culture plates and 200 μl of each BALF concentration 
was placed in duplicate wells then incubated at 37°C, 5% CO2 incubating chamber for 90 
minutes. After this initial sample incubation, 1 ml of culture media was added to each well and 
the plates were further incubation for 48 hours at 37°C, 5% CO2.  
Fluorescent staining of the viral infected cells was performed by adding 60% 
acetone/40% methanol fixative solution for 1 minute. The fixing solution was removed, and 
the plates were air-dried then rehydrated with 1 ml Tris buffer saline with 0.05% Tween 
(TBST)/well. TBST was removed and 1 ml blocking solution (3% BSA (Fisher Scientific, 
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Hanover Park, IL, USA) in TBST) was added to each well and incubated for 30 minutes at 
room temperature. The blocking solution was removed, and primary polyclonal goat anti-RSV 
(EMD Millipore, Billerica, MA) diluted to 1:800 with 3% BSA in TBST was added (325 
μl/well) and incubated at 4°C, overnight on a rotator. All wells were washed 3 times with TBST 
and then 1:800 diluted secondary fluorescence tagged rabbit anti-goat IgG (Alexa Fluor® 488 
F(ab’)2 fragment of rabbit anti-goat IgG (H+L), Molecular Probes/Life Technologies) with 3% 
BSA in TBST was added in to each well (325 μl/well). After 30 minutes of incubation at room 
temperature, the plates were washed three times with TBST and 1 ml of TBST was added in 
each well to prevent drying. Fluorescent plaques were counted under an inverted fluorescence 
light microscope and viral titers (FFU/ml) were calculated by averaging the number of plaques 
in the duplicate wells. 
 
Real-Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR) 
Lung tissue samples from the right cranial, left cranial, left middle and left caudal lung 
lobes (~0.3 g/lobe) of each lamb was pooled and homogenized in 12 ml TRIzol solution 
(Invitrogen/Life Technologies, Carlsbad, CA, USA) for RNA extraction. A total volume of 1.1 
ml of the lung homogenate in TRIzol solution from each sample was mixed with 120 μl of 
chloroform then centrifuged at 12,000 x g, 4°C. After centrifugation, 550 μl of the upper 
aqueous layer was collected from each sample and mixed with 500 μl of isopropanol for 10 
minutes. The precipitated RNA was collected by centrifuging the samples for 10 minutes at 
12,000 x g, 4°C. The final RNA pellets were resuspended in 170 μl nuclease-free water and 
heated for 90 seconds at 60°C. Subsequently, 70 μl of each RNA extracted sample was treated 
with DNase (TURBO-DNase, Ambion, Austin, TX, USA) then 80 μl of the samples were 
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diluted 1:10 with nuclease-free water (710 μl) and RNaseOUT (10 μl) (Invitrogen/Life 
Technologies, Carlsbad, CA, USA). The amount of RNA was measured using 
spectrophotometry at wavelength of 260/280 nm.  
At necropsy, 100 μl of each BALF sample was store at -80°C in 1 ml TRIzol solution 
until RNA isolation. The process of RNA isolation for BALF samples was performed 
according to TRIzol procedure (Invitrogen/Life Technologies, Clarlsbad, CA, USA) to obtain 
sample RNA pellets. Each pellet was collected and resuspended in 100 μl of nuclease-free 
water (Invitrogen/Life Technologies, Carlsbad, CA, USA) and incubated at 60°C for 2 
minutes. The final RNA insolated BALF samples were diluted 1:10 with nuclease-free water 
(710 μl) and RNaseOUT (10 μl) (Invitrogen/Life Technologies, Carlsbad, CA, USA). 
Quantification of hRSV viral particles with RT-qPCR was performed on RNA isolated 
of lung and BALF samples by targeting the nucleoprotein (N) mRNA of M37 RSV. The 
primers and probe for the RSV M37 nucleoprotein (N) mRNA sequence in this study were 
designed using ABI Primer Express 2.0 based on RSV GenBank accession number M74568 
(Supplementary Table 2). Cytokines/chemokines (IFN-λ, IL-13, MCP-1 (CCL2), MIP-1α 
(CCL3), RANTES (CCL5), IP10 (CXCL10)), PD-L1 (CD274), and CC10 mRNA expressions 
were evaluated in the lung samples with primer and probe sequences of all targets listed in 
Supplementary Table 2. RT-qPCR was conducted using One-Step Fast RT-qPCR Kit master 
mix (Quanta, Bioscience, Gaithersburg, MD, USA) in a Gene Amp 5700 Sequence Detection 
System (Applied Biosystmes, Carlsbad, CA, USA). The amount of PCR reagents were 
calculated and managed using PREXCEL-Q software [8]. Each sample was duplicated and 
placed in the thermocycler for one round of pre-treatment (3 minutes at 50°C, then 30 seconds 
at 95°C) followed by 45 cycles of 3 seconds, 95°C and 30 seconds at 60°C. The virus copy 
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number was calculated based on the standard curve generated from a plasmid construct. The 
relative quantity (rQ) of cytokine/chemokine and CD274 and CC10 mRNA expression was 
calculated from sample mixture (Stock I) with the following equation: rQ=10[(Cq − b)/m] where Cq 
represents the cycle time value, b is the y-intercept and m is the slope from the standard curve 
of Stock I [8]. 
 
Immunohistochemistry (IHC) Detection of HRSV Antigen 
Tissue cassettes containing lung samples were processed by the Histopathology 
Laboratory, Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State 
University for hematoxylin and eosin (H&E) stained slides and unstained slides for 
immunohistochemical detection of hRSV antigen. For immunohistochemistry, the slide 
sections were placed in heated oven (58C) and directly immersed in xylene for 
deparaffinization process. The slides were then rehydrated through gradient alcohol (100%, 
95%, 70% methanol) with initial endogenous peroxidase blocking (3% hydrogen peroxide in 
methanol solution) then placed in double distilled water (ddH2O). Antigen retrieval process 
was performed by placing the slides in pH 9.0 19 mM TRIZMA Base, 1 mM EDTA buffer and 
0.05% Tween 20 and heated at 125°C using pressure-cooking device (Decloaking Chamber 
Plus, Biocare Medical, Concord, CA, USA). Subsequent steps of IHC staining were performed 
using programmed IHC automated machine (BioGenex OptiMax i6000 staining system, USA). 
The protocol consisted of serum blocking with 3% bovine serum albumin (BSA) in Tris buffer 
saline with 0.05% Tween (TBST), then with 20% normal swine serum (NSS) in TBST for 15 
minutes each. The slides were then incubated with primary antibody for 90 minutes (1:500 
polyclonal goat anti-RSV antibody (Millipore/Chemicon, Darmstadt, Germany) in 10% NSS, 
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3% BSA in TBST solution. Subsequently, the slides were washed twice with PBST then 
incubated for 45 minutes with 1:300 dilution of biotinylated rabbit anti-goat IgG antibody in 
10% NSS, 3% BSA in TBST solution. Secondary peroxidase blocking was performed by 
incubating the tissue section in 3% H2O2 in TBST for 25 minutes followed by two TBST 
washes. Next, the slides were incubated in 1:200 streptavidin-horseradish peroxidase diluted 
in TBST for 30 minutes and washed 3 times with TBST. The slides were manually stained 
with chromogen substrate (Nova Red staining solution) for 60-90 seconds and immediately 
placed in tap water to stop the reaction. Shandon’s hematoxylin was used as nuclear 
counterstain. 
 
Lung HRSV Lesion Evaluation 
The macroscopic and microscopic lung associated hRSV lesions were examined and 
scored with a semi-quantitative system in order to evaluate and compare the extent of virus 
associated lung pathology. The macroscopic lung scores were based on the average percentage 
of dark-red consolidated areas distributed in each lung lobe and converted to scoring scale from 
0 to 4 (e.g. 0% = 0, 1-9% = 1, 10-39% = 2, 40-69% = 3, 70-100% = 4). Lung histopathological 
scores were determined with H&E staining of two representative lung tissue sections taken 
from each right cranial, left cranial, left middle and left caudal lung lobes of each lamb. Criteria 
for scoring (0 to 4 from lowest to highest pathological changes) include; microscopic lung 
consolidation, bronchitis, syncytial formation, bronchial and bronchiolar epithelial necrosis, 
bronchial and bronchiolar epithelial hyperplasia, presence of neutrophilic infiltration, 
perivascular and peribronchiolar lymphocytic infiltrates (Table 1). The degree of hRSV 
antigen detected with IHC was evaluated by counting the number of bronchioles and alveoli 
 80 
with positive hRSV antigen signal in 20 fields at 100X (field number 22) per slide each 
containing sections from right cranial, left cranial, left middle and left caudal lung lobes from 
each lamb (e.g. score 1=1-10 positive counts, score 2=11-39 positive counts, score 3=40-99 
positive counts and score 4=>100 positive counts).  
 
In Situ Hybridization (RNAscope®) 
Viral RNA was detected in formalin-fixed paraffin embedded (FFPE) lung tissue by 
RNA in situ hybridization (RNAscope®, ACD Bio) assay [9] with probe sequence targeting 
the nucleoprotein (N) of hRSV Memphis 37 (Cat No. 439861). Briefly, the FF E lung tissue 
blocks were sectioned at 5 m thickness and deparaffinized with 100% ethanol solution. Next, 
endogenous peroxidase activity was blocked with hydrogen peroxide for 10 mins at room 
temperature, and then slides were heat treated by boiling with Target Retrieval Reagent® for 
15 mins and enzymatic treatment with Protease Plus® at 40C for 30 mins. Subsequently, probe 
hybridization (2h at 40C) and amplification of the viral RNA target were conducted in 
HybEZTM Hybridization System and RNAscope® 2.5 Assay platform. Positive control probe 
(PPIB) and negative control probe (DapB) were concurrently tested. The amplified viral target 
was stained with 3,4’-diaminobenzidine (DAB) chromogenic substrate (RNAscope® 2.5 HD 
Detection Reagent-Brown) and counterstained with hematoxylin.  
The positive signal from RNA in situ hybridization was evaluated using manual light 
microscopic evaluation and image analysis software (HALOTM). The bronchioles and alveoli 
with positive signal were manually counted then calculated based on 400 mm2 of the 
pulmonary section. A total of twenty histological images taken at (200X) of the lung 
representing each lamb were analyzed through image analysis software. Cell-by-cell 
 81 
expression profiles were quantified into different bin (Bin 0; <1 copy/cell, Bin 1; 1-3 
copies/cell, Bin 2; 4-9 copies/cell, Bin 3; 10-15 copies/cell, Bin 4; (>15 copies/cell). Histo 
score (H score) of each image were calculated from the sum of the bin number were multiplied 
by the percentage of cells per bin [9, 10]. The averaged H score from the analyzed images 
represented the level of viral RNA detected by RNA in situ hybridization in each lamb. 
 
Statistical Analysis 
 The quantitative data were evaluated on GraphPad Prism 6 statistical software with 
Kruskal-Wallis non-parametric test or with Dunn’s multiple comparisons test to calculate 
significant statistical differences (p<0.05) between each experimental group. The results from 
viral titer, viral mRNA, and chemokines/cytokines mRNA expression were statistically 
analyzed. Due to unexpected death loss of the positive control RSV group, viral titer and 
mRNA data from previous experiments with similar conditions (e.g. age, dose of infection, 
duration after viral inoculation) were included to calculate the statistical analysis. Correlation 
of multiple variables (Spearman r) were performed on the viral FFU titer, quantification of 
virion by RT-qPCR, IHC score and H score obtained from RNA in situ hybridization. 
 
Results 
Clinical signs and symptoms associated with hRSV infection 
 Clinical parameters including body temperature, body weight, heart rate and respiratory 
rate were within the normal range in all lambs. Increased respiratory effort were detected at 6 
dpi in 1/3 lambs of RSV, 0/5 lambs in T50, 1/3 lambs in T10, and 1/4 lambs in T2. Wheezing 
or coughing were not observed in any treatment group throughout the course of study. 
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Pharmacokinetic of Replicator Inhibitor JNJ-64166037 
The replicator inhibitor (JNJ-64166037) plasma concentration levels increased in a dose 
dependent manner with Ctrough levels maintained at more than or equal to 1400, 277, 120 ng/ml 
under high dose (T50), medium dose (T10) and low dose treatments (T2), respectively (Fig 1). 
Exposure of JNJ-64166037 was on average higher in lavaged-lung tissue as compared to the 
epithelial lining fluid (ELF). The lung to plasma ratio was 0.72 and ELF to plasma ratio was 
0.10 in the T50 group indicating moderate distribution of the compound into the lung. 
 
Viral Titer and Viral RNA detection 
Both the average virus titers determined by FFU and viral mRNA level determined by 
RT-qPCR in BALFs were higher than in the lung homogenates. Viral titer and mRNA levels 
in the treatment groups from both BALF and lung samples were reduced compared to the 
untreated group in a dose-dependent manner. The hRSV FFU viral titers were below the 
detection level in all lung samples and in 1 of 5 BALF samples from the high dose group (T50). 
The geometric means of the viral titer in BALF samples were 1.23x102, 2.54x104, 7.85x104, 
3.60x104 FFU/ml, and in the lung samples were 0, 9.20x102, 1.36x104, 1.51x104 FFU/g in T50, 
T10, T2, and RSV respectively. The viral titer in BALF and lung in the high dose group (T50) 
were significantly lower (p<0.05) compared to the low dose group (T2). In addition, the viral 
titer in the lung of T50 was significantly reduced compared to the non-treated group (RSV) 
(Fig 2a, 2b). No viable virus was detected by FFU in both BALF and lung samples of the 
negative control group. 
A similar trend of dose-dependent reduction in RSV was demonstrated with the level 
of viral mRNA detected by RT-qPCR. The geometric means of the viral mRNA level in BALF 
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samples were 1.67x105, 2.41x107, 8.08x107, 9.66x107 virion/ml, and in the lung samples were 
2.66x106, 1.07x109, 3.76x109, 4.71x108 virion/g in T50, T10, T2, and RSV group, respectively. 
The level of hRSV virion in the high dose group (T50) was significant lower compared to the 
number of virions detected in the BALF (p<0.05) and lung (p<0.01) of the low dose group 
(T2), and the virion level in the non-treated group (RSV) only in the BALF sample (p<0.01) 
(Fig 2c, 2d). No hRSV mRNA was detected in either BALF or lung samples of the negative 
control group. 
 
Lung Pathology and Detection of HRSV in Pulmonary Histological Tissue 
The macroscopic lung lesions related to hRSV infection at 6 dpi appeared as multifocal 
3-5 mm, dark-red consolidated areas involving the cranial and accessory lobes, and in more 
severe cases, extended into the caudal lobes (Fig 3). Total percentage involvement of hRSV 
lung lesions grossly was calculated by averaging the value assessed in each lung lobe. A higher 
percentage of lung lesions were present in low dose treatment group (T2) (51.6%) followed by 
intermediate dose (T10) (26.7%) and no macroscopic lesions were seen in the high dose group 
(T50) (0.00%) (Fig 4). Microscopic lung lesions of hRSV-infected neonatal lambs were 
characterized by necrotizing and neutrophilic bronchiolitis with lymphoplasmacytic adventitial 
infiltrates and syncytial cell formation with the average microscopic lung consolidation score 
of 2.08/4 (Fig 3). The average microscopic lung consolidation scores were higher in the low 
dose group (T2) (2.25/4), followed by intermediate dose (T10) (0.83/4) and were the lowest 
(score of 0/4) in the high dose group (T50) (Fig 4). In addition, the scores of bronchiolitis, 
syncytial formation, epithelial necrosis, epithelial hyperplasia, neutrophilic infiltrates, 
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peribronchiolar and perivascular lymphoplasmacytic infiltrates, had a similar trend between 
the treatment groups (Fig 4).  
The hRSV antigen was identified by immunohistochemical staining of lung and was 
present in intact and sloughed bronchiolar epithelial cells, syncytial cells and type II 
pneumocytes (Fig 5). Occasionally, hRSV antigen was detected in pulmonary alveolar 
macrophages. Immunohistochemical staining of hRSV antigen in lung were scored based on 
the number of immunoreactive cells evident in the bronchioles and alveoli. Viral antigen was 
not detected in 2/5 lungs sampled from the high dose group (T50). The average 
immunoreactivity scores in the bronchioles and alveoli were significantly lower in high dose 
group (T50) (bronchioles = 0.080.11, alveoli = 0.050.11) compared to placebo group (RSV) 
(bronchioles = 1.710.39, alveoli = 2.960.82) and low dose group (T2) (bronchioles = 
1.810.30, alveoli = 3.001.29) (Fig 6). 
The viral hRSV RNA was detected within bronchiolar epithelial cells, type II 
pneumocytes and pulmonary alveolar macrophages via RNA in situ hybridization 
(RNAscope®). The virion detection appeared as brown DAB chromogenic staining 
characterized as dots where a single dot representing a single probe binding equivalent to a 
single copy of virion. With software image analysis, the density of the dots within each cell 
were calculated and graded in 4 tier bin; Bin 0; <1 copy/cell, Bin 1; 1-3 copies/cell, Bin 2; 4-9 
copies/cell, Bin 3; 10-15 copies/cell, Bin 4; (>15 copies/cell) and further calculated into a 
quantitative H-score representing the degree of hRSV RNA virion expression in the lung. All 
infected lung samples had positive staining for hRSV virions. The overall percentage of 
positive cells were highest in low dose treatment group (T2, 11.52%) followed by intermediate-
dose treatment (T10, 5.27%) and lowest in the high-dose treatment (T50, 0.26%). Similarly, 
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the mean H-score of the lungs were lowest in the high-dose treatment group (T50) (0.450.64) 
with increasing scores in the intermediate-dose group (T10) (13.613.56) and the highest 
scores in the low-dose treatment group (T2) (31.4514.50). The hRSV infected group with no 
treatment had an average H-score of 19.5220.65. There was a statistically significant 
differences of H-score was presented between the high dose group (T50) and the low dose 
group (T2) (p<0.001) (Fig 6). There was a strong correlation (p<0.001) between H score and 
IHC bronchiole lung score (r=0.908), lung viral FFU titer (r=0.837), FFU viral level (r=0.784), 
lung RT-qPCR viral level (r=0.801), BALF RT-qPCR (r=0.757) and IHC alveolar score 
(r=0.768). 
 
Cytokine and Chemokines mRNA Expression 
Evaluation of cytokine and chemokine mRNA expression demonstrated an increasing 
trend of CXCL10 (IP10), CCL2 (MCP-1), CCL3 (MIP-1α), CD274 (PD-L1) and IFN-λ in 
RSV-infected with no treatment (RSV) and low dose groups (T2) corresponding with higher 
viral load of these groups. Significant differences were observed in CCL2 (MIP-1α) levels 
between T50 and T2 and IFN-λ level of negative control group and T2. No significant 
differences or decreasing/increasing trend were observed in the level of RANTES and IL-3 
mRNA expression (Fig 6). 
 
Discussion 
Infection of hRSV in immunocompetent adults often results in mild bronchiolitis, but 
can manifest as acute respiratory tract infection (ARTI) or severe acute respiratory infection 
(SARI) in infants and elderly individuals resulting in hospitalization and fatalities. There is 
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currently a need to develop effective methods of prevention and treatment of hRSV. Extensive 
laboratory and preclinical animal studies and testing are necessary on pharmaceutical 
compounds and vaccines prior to clinical phases of evaluation. Parameters accessed during 
`the preclinical development of these compounds include their intrinsic antiviral activity, 
safety/tolerability, developability, pharmacokinetics/pharmacodynamics, and the 
characterization of antiviral resistances. Antiviral activity tests require the use of experimental 
models for hRSV infection. An in vitro model of well-differentiated primary pediatric 
bronchial epithelial cells (WD-PBECs) has been developed and ascertained to be beneficial for 
hRSV pathogenesis research though there are limitation of this model for therapeutic and 
vaccination studies [10, 11]. Alternatively, reconstitution of 3D human airway epithelium cells 
(HuAECs) have been demonstrated to be a relevant ex vivo model for studying the efficacy of 
antiviral compounds [12]. However, animal models and assessment in vivo still remain 
indispensable for validating the antiviral compounds penetrating ability into the target organ 
at the appropriate level and time of exposure. 
Several animal models of in vivo hRSV infection have been established and these 
include cotton rats [13, 14], laboratory mice [15, 16], ferrets [17], non-human primates (NHPs) 
[18, 19], and neonatal lambs [5, 6] which were used in this study. As a representative model 
for human infant lungs [5], the neonatal lambs infected with hRSV Memphis 37 virus 
developed pulmonary lesion characterized by necrotizing and neutrophilic bronchiolitis, with 
lymphoplasmacytic adventitial infiltrates and occasional syncytial cell formation with hRSV 
localizing in bronchiolar epithelium and occasionally in type II pneumocyte with peak lesion 
development at 6 dpi [20]. All the hRSV infected, positive control lambs (RSV) in this study 
had effective viral inoculation with similar pulmonary lesions as previously described. Studies 
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of therapeutic efficacy of compounds have been tested in neonatal lamb model of hRSV 
infection in infants and some have advanced into the clinical phase. The aerosolized 
compound, ALX-0171 in neonatal lambs had robust antiviral effect in reducing the pulmonary 
lung lesion even with late term dosing [21]. In addition, oral administration of fusion inhibitor 
compound, JNJ-53718678, had a potent effect in reducing the lung viral load and pulmonary 
lesion in hRSV-infected lambs [22]. 
Various hRSV antiviral compounds have been developed including fusion protein 
inhibitors [22-25], and non-fusion protein inhibitors that target G protein [26], viral RNA 
polymerase [27, 28], viral mRNA guanylylation [29] and viral nucleoprotein (N) [30]. The 
mechanism of fusion protein inhibitors is through the binding to the fusion protein in the pocket 
of the trimeric ectodomain of the metastable prefusion F protein, thus stabilizing the prefusion 
conformation and inhibiting viral entry [31]. Even with the structural differences of the fusion 
protein inhibitor compound, possible cross-resistance mutation of the virus has been identified 
in experimental settings [32] and with fusion inhibitors for other viruses [33]. Moreover, the 
effective treatment window reported in vitro with fusion inhibitors is limited in time with a 
potential loss of the antiviral effect once the virus has entered the cells, but the faculty of 
blocking the entry of the virus in neighboring cells. Also, considering the threat associated to 
the emergence of antiviral resistance (all fusion inhibitors published so far share the same 
binding pocket), an alternative mode of action is desirable. HRSV replication inhibitors that 
inhibit post-entry pathway of viral replication have shown a wider effective treatment window 
up to 3 days post infection when tested in the HuAEC model [12]. Efficacy of JNJ-64166037 
replication inhibitor in neonatal lambs infected with hRSV was evaluated for antiviral efficacy 
but also for its impact on the hRSV-induced pathology: changes in clinical parameters and 
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degree of pulmonary lesion. No significant differences of general clinical parameters (RR, BW, 
BT and HR) were detected upon infection or modulated by the antiviral treatments. Increased 
respiratory efforts were seen in animals in the intermediate dose (T10), low dose (T2) and non-
treatment group (RSV), but none in the high dose treatment group. The reduction of hRSV 
viral titer and RNA in the lung and BALF of treated lambs were dose-dependent. Oral 
administration of the hRSV replicator inhibitor in a single dose per day (q.d.) regimen with the 
first dose given at 1h post-inoculation for a duration of 6 days at 50 mg/kg dosage was most 
effective by significantly reducing hRSV infective viral titer at more than 2 log FFU/ml(g) in 
BALF and/or lung compared to the non-treated hRSV infected group. There were marked 
significant decreases of hRSV virions in the lung samples of lambs given 50 mg/kg regime at 
more than 2 log virion/g compared to the non-treated group. 
Localization of hRSV antigen in lung tissue was determined with 
immunohistochemistry and in situ hybridization of viral RNA. The sensitivity of the in situ 
hybridization detection of viral RNA was higher (100%) than immunohistochemical detection 
of antigen (87.50%). With semi-quantitative scoring of immunoreactive cells in the 
bronchioles and alveoli, there was a significant decrease in the number of immunoreactive cells 
in the high dose treatment group (T50) when compared to the non-treatment group (RSV). 
Quantitative evaluation via image analysis software and calculation of modified H-score 
quantification method identified a similar dose-dependent trend of decreasing viral levels with 
significant differences between the high dose group compared to the low dose group. Overall 
positive signal in the high dose treatment group was very low (0.26%) with low expression of 
viral mRNA in the cells. The higher level of H score and presence of multiple clusters in lower 
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dose treatment groups and non-treated group would suggest a more active replication of the 
virus and cell to cell spread from hRSV infection.  
With image analysis software, cell-by-cell expression profiles were grouped in 4-bins 
and percentages of expression level between treatment groups compared. This method can be 
utilized in interpreting the level of viral mRNA replication within the infected cells and 
effectiveness of the antiviral replicator inhibitor as well as effectively localizing the viral RNA. 
Interestingly, the H score level had significant correlation with the amount of hRSV viral 
antigen measured by FFU and RT-qPCR indicating effective predictive value of the viral level. 
This correlation indicate that the computer analysis and modification of scoring generated can 
represent the viral load in the lung tissue. Similar profiling of virions with RNA in situ 
hybridization have recently been performed in a few studies of other viral infection and 
pathogenesis [34]. An increasing number of studies have utilized this non-antibody based novel 
technique to localize virus antigen including Zika virus in ocular tissue of mice [35] and 
detection of Seneca virus-induced vesicular lesion in swine [36].  
 
Conclusions 
Oral administration of the non-fusion replication inhibitor JNJ-64166037 at the 
appropriate dose has potent antiviral effects in the lamb model of RSV infection by decreasing 
the level of hRSV in a dose-dependent manner. This mode of therapeutic intervention 
eliminated the hRSV-induced lung lesions assessed in the model. This study provides 
promising evidence that JNJ-64166037 might prove to be an effective treatment for RSV 
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Figure 1: Plasma compound level of JNJ-64166037 
The level of JNJ-64166037 in plasma of 50 mg/kg (T50), 10 mg/kg (T10) and 2 mg/kg 
(T2) treatment groups evaluated at different time points. The time of treatment compound 



































Figure 2: Viral titer level in BALF and lung detected with focus forming unit assay (FFU) 
and RT-qPCR 
Levels of viral titer in BALF (a) and lung (b) detected by FFU and viral RNA detected in BALF 
(c) and lung (d) by RT-qPCR in different treatment groups (hRSV-infected non-treated lambs 
(RSV, n=6), 50 mg/kg treatment (T50, n=5), 10 mg/kg treatment (T10, n=3) and 2 mg/kg 


























Figure 3: Gross and microscopic lesions in lung in vehicle and replication inhibitor treatment groups 
Gross and microscopic lesions in lung in hRSV-infected non-treated lambs (RSV), 50 mg/kg treatment (T50), 10 mg/kg treatment 
(T10) and 2 mg/kg treatment (T2). 
 







 CS BR SYN EN EH NEU BN VN 
RSV 2.081.28 1.750.87 0.500.50 1.170.52 1.830.80 1.750.90 1.671.18 1.500.75 
T50 0 0 0 0 0 0 0 0 
T10 0.830.52 0.920.58 0.670.52 0.670.58 0.670.58 0.830.52 0.830.52 0.830.52 
T2 2.250.35 1.630.43 0.880.48 1.310.38 1.310.38 1.560.38 1.500.35 1.500.35 
Neg 0 0 0 0 0 0 0 0 
CS; microscopic consolidation, BR; bronchiolitis, SYN; syncytial formation, EN; epithelial necrosis, EH; epithelial hyperplasia, NEU; 
neutrophilic infiltrates in airways, BN; peribronchiolar lymphoplasmacytic infiltrates, VN; perivascular lymphoplasmacytic infiltrates 
 
Figure 4: Percentage of HRSV-associated lung lesion and HRSV-associated microscopic lung 
score  
Scoring of the macroscopic (bar) and microscopic (line) lung lesions were based on 
percentages of grossly affected lung parenchyma and microscopic score of consolidation in 
neonatal lamb of different experimental groups; RSV-infected with no treatment (RSV), 50 



































































Figure 5: Immunohistochemical detection of hRSV antigen and RNA in situ hybridization  
Immunohistochemical detection (top row) of RSV antigen (Nova red stain, 200X) and RNA in situ hybridization (bottom row) (DAB, 
200X) in 50 mg/kg treatment (T50), 10 mg/kg treatment (T10) and 2 mg/kg treatment (T2) compared to hRSV-infected non-treated 
group (RSV).
T2 RSV T10 T50 
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Figure 6: Immunoreactivity score and RNA in situ hybridization H score of hRSV 
Immunohistochemical scores (left) of hRSV antigen detected in the lung section of each 
treatment group. Significant differences were observed between the level of virus in the 50 
mg/kg treatment (T50) compared to non-treatment group (RSV) and 2 mg/kg treatment (T2). 
The level of H score of hRSV detected with RNA in situ hybridization (right) increased in a 
dose-dependent manner. Significant reduction of H score was observed when administered 50 






















Figure 7: Cytokine and chemokine mRNA expression (IP-10, MCP-1, MIP-1α, PD-L1, 
RANTES, IFN-, and IL-13) 
Cytokine and chemokine mRNA expression (IP-10, MCP-1, MIP-1α, PD-L1, RANTES, IFN-
, and IL-13) displaying individual data points and geometric mean values (horizontal bar) of 
each treatment (50 mg/kg (T50), 10 mg/kg (T10) and 2 mg/kg (T2)) and non-treated group 
(RSV). 
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Abstract 
Background: The purpose of this study was to determine the antiviral efficacy when 
administering a combination of inhibitors with distinctly different modes of action (fusion 
protein and non-fusion protein inhibitors) and investigate the time window in which 
monotherapy or combination therapy may be efficacious. This preclinical drug trial was 
performed in hRSV-infected neonatal lambs which are a model for hRSV infection of human 
infants that develop similar severe lung pathology. 
Methods: The experiment was divided in two phases; a Phase I combination efficacy 
study and a Phase II treatment time window study. In both phases, 1-3 day(s) old lambs were 
infected with hRSV Memphis 37 by viral nebulization. In the Phase I combination efficacy 
study, combination treatment of hRSV fusion inhibitor and replication inhibitor was 
administered orally once daily starting at 24 hours after infection, and was compared with 
monotherapy of the fusion inhibitor or the replication inhibitor given in the same manner. The 
doses of the antiviral compounds were based on the ED50 dose response curve from previous 
in vitro studies. For the Phase II treatment time window study, administration of combination 
treatment was delayed to day 3 and 4 post-infection and was compared to similarly delayed 
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monotherapy treatment with the fusion inhibitor or replication inhibitor. All animals in both 
phases were euthanized at day 6 post-infection. Bronchoalveolar lavage fluid (BALF) and lung 
tissue samples were collected for quantification of viral load (focus forming unit assay (FFU) 
and real-time reverse transcriptase polymerase chain reaction (RT-qPCR)), and localization of 
viral antigen in lung tissue (immunohistochemistry (IHC) and RNA in situ hybridization 
(RNAscope)). In addition, disease severity was assessed by clinical parameters, macroscopic, 
microscopic lung examination and expression of cytokines. Evaluation of cytokine mRNA 
expression (IFN-λ, IL-13, MCP-1 (CCL2), MIP-1α (CCL3), RANTES (CCL5), IP10 
(CXCL10)) and expression of immune-related molecules against hRSV (PD-L1 (CD274) and 
CC10) were performed on lung tissue samples. 
Results: The viral titer levels with combination therapy in BALF were reduced up to 
28-fold with high dose (4 mg/kg fusion inhibitor and 0.75 mg/kg replication inhibitor) and 11-
fold with low dose (2 mg/kg fusion inhibitor with 0.4 mg/kg replication) when compared to 
the non-treated group. Administration of the combination treatment had lower level of viral 
titer levels, compared to monotherapy with fusion (1.7=fold) or non-fusion inhibitors (2.46-
fold) given at identical doses. At the high dose level of combination therapy (4 mg/kg fusion 
inhibitor and 0.75 mg/kg replication inhibitor), there was prominent reduction of viral titer. 
Monotherapy treatment of replication inhibitor alone at 0.4 mg/kg did not significantly reduced 
the amount of virus compared to non-treated lambs (7.67x108 virions/ml BALF), although the 
average level of the viral titer appeared lower (6.80x107 virion/ml BALF). The viral loads 
paralleled the observed degree of lung pathology.  
The delayed administration of combination therapy at day 3 and day 4 post-infection 
as well as monotherapy with the replication inhibitor (4 mg/kg) at day 3 post-infection resulted 
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in significant reductions in viral load compared to fusion inhibitor monotherapy and non-
treated lambs. Lung lesions had a slightly different pattern at this timepoint in which the 
combination treatment had a similar degree of lung lesion severity as the fusion inhibitor 
monotherapy while the replication inhibitor had increased lesion severity. 
Conclusion: Administration of combination drug therapy against hRSV holds 
promising potential as a future treatment option in clinical settings when administered both 
early and late following detection of infection. This combined treatment had potent antiviral 
effects in the hRSV-infected lamb model and demonstrated a prolonged treatment window up 
to 4 days after infection. Furthermore, the neonatal lamb model of hRSV infection appeared 
suitable for antiviral therapeutic testing and pathogenesis studies of hRSV infection. 
 
Introduction 
 Human respiratory syncytial virus (hRSV) is a common cause of acute respiratory tract 
infection (ALRI) in young children worldwide with infection resulting in bronchiolitis and 
pneumonia [1, 2]. Lower respiratory tract infection by hRSV can also be detrimental in elderly 
individuals and contributes to morbidity and mortality of people over the age of 65 in the 
United States [3-5]. Approaches to hRSV prevention, control and treatment relies on successful 
development of vaccines, immunoprophylaxis and antiviral compounds. Despite tremendous 
research and advancements in vaccine and therapeutic development, no vaccine has been 
approved for hRSV in humans. An approved immunotherapeutic compound, palivizumab 
(Synagis), can be used for prophylactic treatment of hRSV, but due to short duration of half-
life, variability of effectiveness and high price, it is not recommended for routine treatment [6-
8]. Ribavirin, an antiviral nucleoside analog that blocks RNA synthesis, is another compound 
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that has been approved for treatment of hRSV, although with limited effectiveness and reports 
of multiple adverse effects [9-12]. A limited number of the pharmaceutical products are 
currently in phases of clinical trials including immunomodulatory compounds [13], small 
molecule inhibitors that target viral fusion protein which is associated with viral entry [14, 15], 
or other small molecules that inhibit the machinery necessary for viral replication such as viral 
RNA polymerase, and nucleoprotein [16, 17]. 
The mechanism of action of current molecule fusion protein inhibitors is through 
binding and stabilizing the metastable prefusion F protein which prevents viral entry and fusion 
with host cells [18, 19]. Cross-resistance mutation of the virus and the early effective treatment 
time window are concerns with using fusion protein inhibitors [18]. Viral replication inhibitors 
target the post-entry pathway of virus infection and have demonstrated a wider effective 
treatment window in laboratory settings [20]. To our knowledge, combination treatment with 
both fusion and replication inhibitors for hRSV has not been tested in any experimental animal 
model.  
Validating the efficacy of therapeutic compound requires the use an appropriate animal 
model in the preclinical phase. The neonatal lamb model of hRSV infection has similarities to 
human infants that include similarity of lung size, airway structures, immunological response 
and lung lesions [21, 22]. In this study, we applied the lamb model for hRSV to test the efficacy 
of oral administration of a combination of a fusion protein inhibitor and non-fusion protein 
inhibitor. Furthermore, we explored the effective therapeutic time window of these compounds 




Materials and Methods 
Animal Model and Experimental Design 
This project was divided into two phases; a study assessing the efficacy of 
administering combination of a fusion protein inhibitor with a non-fusion protein inhibitor 
(Phase I) and a study to evaluate the time window for effective treatment with the combination 
therapy (Phase II). In both phases, 1-3 day(s) old, colostrum-deprived, neonatal lambs were 
infected with a clinical isolate of hRSV Memphis 37 via nebulization with the final amount of 
virus given equivalent to 3.5 x 107 FFU/lamb. A prophylactic antibiotic (ceftiofur sodium, 
Naxcel®) were administered to all animals participating in both phases of the study. 
The treatment groups in the Phase I combination efficacy study included a high dose 
combination group (TxH, n=5) given 4 mg/kg fusion inhibitor with 0.75 mg/kg replication 
inhibitor, a low dose combination group (TxL, n=7) given 2 mg/kg fusion inhibitor with 0.4 
mg/kg replication inhibitor, a low dose group receiving 2 mg/kg fusion inhibitor (TxF, n=7), 
and a treatment of low dose 0.4 mg/kg replication inhibitor (TxNF, n=7). The selected doses 
for both antiviral compounds in TxL, TxF and TxNF groups were at the level of ED50 based 
on previous analysis of dose responses. All compound(s) were administered once daily starting 
24 hours after viral inoculation for a total of 5 consecutive days. 
The Phase II combination treatment window study consisted of four treatment groups 
including a combination treatment of 10 mg/kg fusion inhibitor and 4 mg/kg replication 
inhibitor first given at 3 dpi (TxL3, n=5), a combination treatment of 15.5 mg/kg fusion 
inhibitor and 8 mg/kg replication inhibitor first given at 4 dpi (TxH4, n=5), monotherapy of 
fusion inhibitor (10 mg/kg) first given at 3 dpi (TxF3, n=5) and monotherapy of replication 
inhibitor (4 mg/kg) first given at 3 dpi (TxNF3, n=5). For both phases of the study, five hRSV 
infected lambs were used as positive controls by administering vehicle solution (20% acidified 
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hydroxypropryl-β- cyclodextrin) and three lambs mock infected with pure culture media were 
used as uninfected control. 
Clinical parameters, including body weight, body temperature, respiratory rate, and 
heart rate, were measured daily. Blood collection was performed at different time points to 
evaluate the pharmacokinetics of the compounds in plasma. All lambs were sacrificed at 6 dpi 
with an over-dose of sodium pentobarbital. Necropsy was performed to evaluate the 
macroscopic lung lesion, collect lung samples and bronchoalveolar lavage fluid (BALF). Lung 
tissues were placed in 10% neutral buffered formalin for microscopic examination. Samples 
from right cranial, left cranial, left middle and left caudal lung lobes (0.5 g/each lobe) were 
pooled in 5 ml double-modified Iscove’s media (DMIM) (42.5% Iscove’s modified Dulbecco’s 
medium, 7.5% glycerol, 1% heat-inactivated fetal bovine serum, 49% Dulbecco’s modified 
eagle medium (DMEM) and 5 μg/ml kanamycin sulfate) and stored at 4°C for further 
processing for a viral plaque assay. Separate samples from each lobe were snap-frozen in liquid 
nitrogen and stored at -80°C. The BALF samples were collected from the right caudal lobes in 
5 ml DMIM and stored at 4°C. Animal use and experimental procedure were approved by 
IACUC and IBC at Iowa State University (IACUC# 6-16-8293-O, IBC# 16-I-0028-A/H). 
 
Viral Stock Preparation and Nebulization 
The hRSV virus nebulization was performed as previously described [23, 24]. Briefly, 
human respiratory syncytial virus Memphis 37 strain (hRSV M37) was grown on HEp-2 cell 
line with Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal bovine serum 
(FBS) and 50 g/ml kanamycin sulfate. The extracted virus was diluted with 20% sucrose then 
stored at -80°C until further use. A small sample of the stock virus was collected to determine 
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the amount of virus through viral plaques assay (FFU). In preparation for nebulization, the 
virus stock was thawed and diluted in culture media to obtain 2.5 x 107 FFU/ml. A total of 6 
ml was nebulized to each lamb with PARI LC SprintTM nebulizer to achieve a dose of  
3.5 x 107 FFU/lamb. Pure culture media was nebulized to the negative control group. 
 
Small Molecule Inhibitor Formulation, Administration and Quantification 
Both the fusion protein inhibitor and replication inhibitor were dissolved in 20% 
acidified hydroxypropryl-β- cyclodextrin (20% HP-β-CD + HCl) at pH 7.4 to 0.5 mg/ml and 
0.1875 mg/ml concentrations, respectively. The appropriate dose for each treatment group was 
administered through gavage catheter then followed by 5 ml of 20% HP-β-CD+HCl, pH 7.4 to 
wash down any compound residues. The collected plasma, lung and BALF samples were 
analyzed for treatment compound level by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). 
 
Focus Forming Unit (FFU) 
 Quantification of viral titer was determined by the focus forming unit (FFU) plaque 
assay described previously [25]. Briefly, both BALFs and lung homogenate samples were 
clarified by spin column filter centrifugation. The collected filtrates were stored at 4°C and 
plated within 6 hours after collection. Plating of the samples was performed on previously 
prepared 12-well cell culture plate containing 70-80% confluency of HEp-2 cells at undiluted 
and 10-1, 10-2, 10-3, 10-4 concentrations. The plates were incubated in 37°C, 5% CO2 incubation 
chamber for 48h then inactivated and fixed with 60% acetone/40% methanol solution. Indirect 
immunofluorescence staining was performed using 1:800 primary polyclonal goat anti-RSV 
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(EMD Millipore, Billerica, MA) diluted with 3% bovine serum albumin (BSA) in Tris buffer 
saline with 0.05% Tween (TBST), overnight incubation at 4°C, and 1:800 secondary 
fluorescence tagged rabbit anti-goat IgG (Alexa Fluor® 488 F(ab’)2 fragment of rabbit anti-
goat IgG (H+L), Molecular Probes/Life Technologies) in 3% BSA in TBST, incubated for 30 
min at room temperature. Fluorescent plaques were counted under inverted fluorescence light 
microscope and the FFU/ml calculated from the average number of plaques in the duplicated 
wells.  
 
Real-Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR) 
Quantification of hRSV virions in BALF and lung samples and cytokine/chemokine 
mRNA expression level were assessed by RT-qPCR. In preparation of lung samples, the right 
cranial, left cranial, left middle and left caudal lung lobes (0.3 g each lobe) were pooled from 
each animal and homogenized in 12 ml of TRIzol solution (Invitrogen/Life Technologies, 
Carlsbad, CA, USA). A total amount of 100 ml from each BALF samples were directly placed 
in TRIzol solution. RNA isolation on the prepared lung and BALF samples in TRIzol was as 
previously described [25, 26]. The isolated RNA pellets were resuspended in 170 ul nuclease-
free water. Additional DNase treatment (TURBO-DNase, Ambion, Austin, TX, USA) was 
performed in the isolated lung RNA samples. Both DNase treated lung RNA and BALF RNA 
isolates were diluted at 1:10 in nuclease-free water containing RNaseOUT (Invitrogen/Life 
Technologies, Carlsbad, CA, USA). The amount of RNA from each sample was quantified 
using spectrophotometry (Beckmann DU 640B, Beckmann Coulter Inc., Brea, CA, USA) at 
OD 260/280 nm values. The samples were diluted to the final concentration of 0.7844 ng/l. 
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The primers and probes for RT-qPCR quantification of hRSV and mRNA expression 
of IFN-λ, IL-13, CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES), CXCL10 (IP10), 
CD274 (PD-L1) and CC10 are listed in Supplementary Table 2. All primers and probes were 
generated using ABI Primer Express 2.0 software. RT-qPCR was performed using One-Step 
Fast qRT-PCR Kit master mix (Quanta, Bioscience, Gaithersburg, MD, USA) in a Gene Amp 
5700 Sequence Detection System (Applied Biosystmes, Carlsbad, CA, USA). Prior to running 
the real-time thermocycler, the PCR reagents were calculated and managed using PREXCEL-
Q software [27]. Each sample was duplicated and placed in the thermocycler for one round of 
pre-treatment (3 min at 50°C, then 30 sec at 95°C) followed by 45 cycles of 30 sec, 95°C and 
30 sec at 60°C. The virus copy number per milligram was estimated based on the standard 
curve generated from amplified plasmid constructs. Standard curve for evaluating 
cytokine/chemokine mRNA level was generated from sample mixture (Stock I). The cycle 
time (Ct) values obtained from each sample were converted to relative quantity level (rQ) with 
the following equation: rQ=10[(Cq − b)/m] where b and m are the y-intercept and slope from the 
standard curve of Stock I [27].  
 
Immunohistochemistry (IHC) Detection of HRSV Antigen 
Immunohistochemical staining of hRSV antigen in lamb lung tissue was completed as 
described previously [25]. Briefly, 5 m thick, formalin fixed paraffin-embedded lung tissue 
sections were processed for hRSV antigen localization by indirect immunohistochemical 
staining. After heat-induced antigen retrieval process (19 mM TRIZMA Base pH 9.0, 1 mM 
EDTA buffer and 0.05% Tween 20 at 125°C for 20 mins), the slides were blocked from non-
specific background binding of antibody with 3% BSA and 20% normal swine serum. The 
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slides then were incubated for 90 min at room temperature with polyclonal goat anti-RSV 
antibody (Millipore/Chemicon, Darmstadt, Germany) diluted 1:500 in 10% NSS, 3% BSA in 
TBST solution and subsequently incubated for 45 min with 1:300 dilution of biotinylated rabbit 
anti-goat IgG antibody in 10% NSS, 3% BSA in TBST solution. Endogenous peroxidase 
blocking was performed with 3% H2O2 in TBST. Streptavidin-horse radish peroxidase at 1:200 
dilution in TBST was incubated on the slides then Nova Red chromogenic substrate was use 
for detection and counterstained with Shandon’s hematoxylin. 
 
Lung HRSV Lesion Evaluation 
The macroscopic and microscopic lung lesions were semi-quantitatively scored to 
evaluate and compare the extent of virus associated lung pathology and completed as described 
previously [25]. The macroscopic lung score was based on the average percentage of dark-red 
consolidated areas distributed in each the lung lobe and converted to the scoring scale from 0 
to 4 (e.g. 0% = 0, 1-9% = 1, 10-39% = 2, 40-69% = 3, 70-100% = 4). Lung histopathological 
scores were determined with H&E stained lung tissue sections taken from each right cranial, 
left cranial, left middle and left caudal lung lobes of each lamb. Criteria for scoring (0 to 4 
from lowest to highest pathological changes) include; microscopic lung consolidation, 
bronchitis, syncytial formation, bronchial and bronchiolar epithelial necrosis, bronchial and 
bronchiolar epithelial hyperplasia, presence of neutrophilic infiltration, perivascular and 
peribronchiolar lymphocytic infiltrates (Supplementary Table 1). The degree of hRSV antigen 
detection with IHC was semi-quantatively scored from a range of 0 to 4 by counting the number 
of bronchioles and alveoli with positive hRSV antigen signal in 20 fields at 100X (FOV 2.2 
mm) per slide each containing sections from right cranial, left cranial, left middle and left 
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caudal lung lobes from each lamb (e.g. score 1=1-10 positive counts, score 2=11-39 positive 
counts, score 3=40-99 positive counts and score 4=>100 positive counts).  
 
In Situ Hybridization (RNAscope®) 
Viral RNA detection was performed in formalin-fixed paraffin embedded (FFPE) lung 
tissue by RNA in situ hybridization (RNAscope®, ACD Bio) assay [28] with probe sequence 
targeting the nucleoprotein (N) of hRSV Memphis 37 (Cat No. 439861). Briefly, the FFPE 
lung tissue blocks were sectioned at 5 m thickness and deparaffinized with 100% ethanol 
solution. Endogenous peroxidase activity was blocked with hydrogen peroxide for 10 mins at 
room temperature. Antigen retrieval consisted of heat treatment by boiling with Target 
Retrieval Reagent® for 15 mins and enzymatic treatment with Protease Plus® at 40C for 30 
mins. Subsequently, probe hybridization (2h at 40C) and amplification of the viral RNA target 
were conducted in HybEZTM Hybridization System and RNAscope® 2.5 Assay platform. 
Positive control probe (PPIB) and negative control probe (DapB) were concurrently tested. 
The amplified viral target was stained with 3,4’-diaminobenzidine (DAB) chromogenic 
substrate (RNAscope® 2.5 HD Detection Reagent-Brown) and counterstained with 
hematoxylin.  
The percentage of stained cells was determined by a semiquantitative method of 
scoring and a quantitative method with image analysis software (HALOTM). The semi-
quantitative method was performed by separate assessment of the number of bronchioles and 
alveoli containing positive signal and calculated based on a 400 m2 lung tissue area. In 
addition, image analyzer software was used to quantify cell-by cell the viral RNA expression 
profile and categorize the cells in different bins based on the expression level (Bin 0; <1 
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copy/cell, Bin 1; 1-3 copies/cell, Bin 2; 4-9 copies/cell, Bin 3; 10-15 copies/cell, Bin 4; (>15 
copies/cell).  Furthermore, H score of each image was calculated by the sum of the bin number 
multiplied by the percentage of cells per bin. The percentages of hRSV mRNA expression 
were calculated with the image analyzer from 20 histological images taken from the stained 
slides (200X, field number 22).  
 
Statistical Analysis 
 The quantitative data were evaluated with GraphPad Prism 6 statistical software using 
a Kruskal-Wallis non-parametric test and Dunn’s multiple comparisons test to calculate 
significant statistical differences (p<0.05) between each experimental group. The results from 
viral titer, viral mRNA, and chemokines/cytokines mRNA expression were statistically 
analyzed. Due to the low number and high variations on mRNA expression, the positive (n=25) 
and negative control RSV group (n=21) from previous experiments under similar conditions 
(e.g. age, dose of infection, duration after viral inoculation) were included to calculate the 
statistical analysis. Correlation of multiple variables (Spearman r) were performed on the viral 




Pharmacokinetic of Fusion Protein Inhibitor and Replication Inhibitor 
Both of the trough plasma concentration (Ctrough) of small molecule inhibitors in all 
treatment groups maintained a stable increasing trend throughout the treatment period in the 
Phase I study (Fig 1). Slight difference in Ctrough levels of fusion inhibitor was detected between 
the combination treatment (TxL) compared to the fusion inhibitor monotherapy administered 
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at the same dose (TxF). Likewise, the level of replication inhibitor plasma concentration 
detected in the combination treatment (TxL) was lower than replication inhibitor monotherapy 
(TxNF). 
The fusion inhibitor compound was above detection level in all lung and ELF samples. 
The average concentration of fusion inhibitor distribution in TxL, TxH and TxF treatment 
groups were 949.4 ng/g, 4496 ng/g and 1816 ng/g in the lungs, and 253.1 ng/ml, 1,127 ng/ml 
and 788.3 ng/ml in ELFs. The average lung replication inhibitor concentration levels were 
917.3 ng/g in the TxL, 1,861 ng/g in the TxH and 1,523 ng/g in the TxNF. The replication 
inhibitor compound in ELFs was below detection level in 3/7 lambs from the TxL and 3/7 
lambs from the TxNF. The average concentration levels of the replication compound in the 
lungs were 111.3 ng/ml in the TxL, 316.8 ng/ml in the TxH and 123.4 ng/ml in the TxNF (Fig 
1).  
The average lung to plasma ratio of the fusion inhibitor compound concentration in the 
TxF, TxL and TxH were 16.21, 13.91 and 20.83, respectively. The average epithelial lining 
fluid (ELF) to plasma ratios of the fusion inhibitor were 5.19 in the TxF, 4.19 in the TxL and 
6.27 in the TxH. The replication inhibitor compound was less concentrated in the lung tissues 
and ELFs compared to the fusion inhibitor. The average lung to plasma ratios of the replication 
inhibitor in the TxNF, TxL and TxH were 2.54, 1.56 and 1.37, respectively. The replication 
inhibitor concentrations in the ELFs were low and undetectable in some samples. The average 
ELF to plasma ratios of replication inhibitor concentrations were 0.20 in the TxNF, 0.18 in the 
TxL and 0.25 in the TxH. 
In the Phase II study, the Ctrough level of fusion inhibitor and replication inhibitor in the 
plasma were maintained above the therapeutic levels demonstrated in the Phase I study (Fig 
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2). Both inhibitor compound plasma Ctrough levels in the high dose combination administered 
at day 4 (TxH4) reached near the level of the low dose combination administered at day 3 
(TxL3). The average level of the fusion inhibitor compound distribution in the lungs at day 6 
in the TxL3 (ELF=19,526.92 ng/ml, lung=25,525 ng/g), TxH4 (ELF=17,187.94 ng/ml, 
lung=32,505 ng/g) and TxF3 (ELF=7,383.10 ng/ml, lung=24,890 ng/g) were measured. The 
level of the replication inhibitor compound distribution in the ELFs was low and undetected in 
two samples (1/5 in TxNF3 and 1/5 TxL3). The average level of replication inhibitor 
concentrations in the TxL3, TxH4 and TxNF3 were 2,966. 26 ng/ml, 3,057. 25 ng/ml and 
1,179.34 ng/ml in the ELFs, and 8,596 ng/g, 13,785 ng/g and 8,651 ng/g in the lungs, 
respectively (Fig 2). 
 
Viral Titer and Viral RNA detection in BALFs and Lung Tissues 
 The combination treatment of fusion protein inhibitor and non-fusion protein inhibitor 
significantly reduced the level of virions detected via FFU assay and RT-qPCR in the lung and 
BALF samples compared to the non-treatment group. The total level of virion RNA in BALF 
samples were reduced up to 28 times in the high dose combination treatment (TxH) and 
reduced by 11 times in the low dose combination treatment (TxL). Higher levels of viable viral 
reduction were demonstrated with the FFU assay up to 600 times in the high dose treatment 
group and 67 times with low dose treatment. This extreme reduction of viable virus with the 
FFU assay may have been influenced by a compound carry-over effect with this technique of 
virus quantification, although this may be unlikely due to the low dose of compound 
administered and the dilution steps that would reduce the compound residues below the activity 
range. The low dose combination administration appeared to reduce the number of virion in 
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BALF and lung at higher level compared to monotherapy of fusion and replication inhibitor 
compound. There was a significantly lower level of virions in the high dose combination 
treatment (TxH) with up to 4-times greater reduction of total virion RNA compared to fusion 
inhibitor monotherapy (TxF) (p<0.05) and 6-times greater reduction compared to non-fusion 
protein inhibitor monotherapy (TxNF) (p<0.01) (Fig 3a-d). 
 Administration of low dose combination therapy at 3 dpi (TxL3) (p<0.001), high dose 
at 4 dpi (TxH4) (p<0.01) and monotherapy of non-fusion inhibitor at 3 dpi (TxNF3) (p<0.05) 
significantly reduced the level of virus detected with BALF and lung samples compared to the 
non-treated hRSV infected group (RSV). The average level of virions detected in the BALF 
were reduced 195, 39 and 36 times in the TxL3 (2.96x105 virions/ml), TxH4 (8.85x105 
virions/ml) and TxNF3 (1.05x106 virions/ml) treatment, respectively. Compared to 
monotherapy of fusion inhibitor at 3 dpi (TxF3), the level of virions in BALF were 
significantly lower in TxL3 (p<0.0001), TxH4 (p<0.05) and TxNF3 (p<0.05) treatment groups. 
The level of virions in the lung was significantly lower only in the TxL3 compared to TxF3 
monotherapy treatment group. The virus titers were below the detection level of FFU assay in 
all treatment groups, although this may have been influenced by a compound carry-over effect 
as previously mentioned. No virions or viable virus were detected in both BALF and lung 
samples of the negative control group (Fig 4a-d). 
 
Clinical Assessments and Lung Pathology 
In both phases of the study, the clinical parameters including respiratory rate, heart rate 
and body temperature of all animals were in the normal range (Fig 5). The body weight 
gradually increased at a similar rate throughout the study period in all groups with the average 
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daily gain ranging from 177 to 217 g/day. One lamb in Phase I study (Lamb#3) from the TxH 
group was weak and bloating from the beginning of the study prior to viral inoculation. Later 
the animal appeared lethargic and was terminated before the end of the study period (4 dpi). 
At necropsy Lamb#3 had lesion of pulmonary edema associated with in utero fetal distress and 
failure to thrive. Evidence of hRSV-associated pneumonia was not observed at necropsy.  
Macroscopic hRSV-associated lung lesions were diminished at 6 dpi in all treatment 
groups with lowest lung involvement percentage (lung%) in the high dose combination group 
(TxH) (0.170.61), followed by low dose combination treatment (TxL) (1.273.62), fusion 
inhibitor treatment (TxF) (2.765.64) and non-fusion inhibitor treatment group (TxR) 
(11.3910.79), respectively (Fig 6). Histological pulmonary lesions of hRSV infected and 
treated lambs were diminished in a fashion similar to the macroscopic lesions where the overall 
histological consolidation score (CS) was zero in TxH and appeared with an increasing severity 
from TxL (0.21/4), TxF (0.25/4) and TxNF (0.71/4), respectively. Features of bronchiolitis, 
syncytial cells formation, bronchiolar epithelial necrosis and hyperplasia, neutrophilic 
infiltration and lymphoplasmacytic peribronchiolar and perivascular cuffs were present in the 
TxF and TxNF treatment groups. Certain histological features were not evident in combination 
treatment regimens; TxH lacked bronchiolitis, syncytial cell formation, bronchiolar epithelial 
necrosis and hyperplasia and neutrophilic infiltration, and TxL lacked syncytial cell formation, 
bronchiolar epithelial necrosis and hyperplasia (Fig 7). 
With the delayed administration of antiviral treatment, the hRSV-associated pulmonary 
lesion appeared the lowest with combination treatment at 3 dpi (TxL3) (lung% = 1.06, CS = 
0.05), followed by fusion inhibitor monotherapy at 3 dpi (TxF3) (lung% = 1.11, CS = 0.2), 
combination treatment at 4 dpi (TxH4) (lung% = 4.66, CS = 0.2) and the highest with 
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replication inhibitor monotherapy at 3 dpi (TxNF3) (lung% = 10.40, CS = 1.05). Microscopic 
features of syncytial cell formation and bronchiolar epithelial necrosis were lacking in all 
treatment regimens with absence of neutrophilic and perivascular lymphoplasmacytic cuffs in 
TxL3 and absence of bronchiolitis in TxH4 (Fig 9, 10). 
 
Histological Detection of HRSV Antigen and RNA in Pulmonary Tissue 
Localization of hRSV viral antigen with IHC and RNA with in situ hybridization 
determined that the virus was within intact and sloughed bronchiolar epithelial cells, and 
occasionally in scattered type II pneumocytes and pulmonary alveolar macrophages. The level 
of hRSV antigen detected with IHC in hRSV-infected, non-treatment group (RSV) was 3.08 
in the bronchioles and 13.03 in the alveoli and the level of viral RNA was 41.25 in the 
bronchioles and 187.5 in the alveoli. The average viral RNA positive signal counts in the lung 
tissues in the RSV group were 73.5/400 m2 in the bronchioles and 340.4/400 m2 in the 
alveoli. The immunoreactivity and viral RNA positive signal were lower in all treatment 
groups compared to the hRSV-infected, non-treated group (RSV). Immunoreactivity of the 
viral antigen was quantified, and the average values appeared in a decreasing manner from 
TxNF (bronchioles=2.77, alveoli=7.46), TxF (bronchioles=0.27, alveoli=0), TxL 
(bronchioles=0.16, alveoli=0.16) and none were detected in high combination dosage, TxH. A 
similar trend was identified when virion RNA was detected with RNA in situ hybridization 
assessed by positive signal counts of the bronchioles and alveoli. The average positive viral 
RNA signal counts in the bronchioles per 400 m2 lung tissue area from TxNF, TxF, TxL and 
TxH treatment groups were 38.09, 14.14, 11.10 and 6.52, respectively. The positive signal 
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counts in the alveoli per 400 m2 lung tissue area from TxNF, TxF, TxL and TxH treatment 
groups were 216.57, 42.82, 27.90 and 29.95, respectively (Fig 8).  
In the Phase II treatment time window study, the average hRSV immunoreactivity had 
highest detection in TxNF3 (bronchioles=2.46, alveoli=3.41), followed by TxH4 
(bronchioles=0.60, alveoli=1.90), TxF3 (bronchioles=0.38, alveoli=0.68) and was not detected 
in TxL3 (Fig 11a-d). RNA in situ hybridization detected viral RNA in all treatment groups. 
The average positive signal viral RNA cell counts in the bronchioles and alveoli per 400 m2 
lung tissue area corresponded with the IHC antigen detection, i.e. highest in TxNF3 
(bronchioles=25.2, alveoli=76.1), followed by TxH4 (bronchioles=13.4, alveoli=45.9), TxF3 
(bronchioles=10.5, alveoli=124.7) and TxL3 (bronchioles=16.0, alveoli=63.3), respectively. 
(Fig 11e-h). All samples from the negative control group lacked evidence of viral infection 
with IHC and RNA in situ hybridization. 
The H score in the non-treatment hRSV-infected group was 12.093.257 with all 
treatment regimens having significantly lower level of H score (Fig 8, 11). The H score levels 
in the Phase I study were low in the combination treatments (TxH=0.250.27 and 
TxL=0.180.10) and fusion protein monotherapy (TxF=0.240.41). Slightly higher H scores 
were detected in replication inhibitor monotherapy (TxNF=2.070.98). The H score level was 
also evaluated for the Phase II treatment time window study with the lowest average score 
detected in low dose combination, 3 dpi treatment group (TxL3) (0.4890.4199), followed by 
TxH4 (0.6980.5330), TxF3 (1.1861.799) and highest in TxNF3 (3.1393.908). There were 
significant correlations (p<0.0001) of H score with viral levels detected by lung RT-qPCR 
(r=0.687), IHC bronchiole score (r=0.696), IHC alveolar score (r=0.698) and semi-quantitative 
scoring of RNA in situ hybridization in bronchioles (r=0.819) and alveoli (r=0.771). 
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Cytokine and CC10 mRNA Expression 
Significant increase of mRNA levels of CXCL10 (IP10), CCL2 (MCP-1), CCL3 (MIP-
1α), CD274 (PD-L1) and IFN-λ were present in M37 hRSV infected lambs (RSV) compared 
to non-infected group. Monotherapeutic administration of non-fusion inhibitor (TxNF) had 
significantly increased level of CCL3 (MIP-1α) and CD274 (PD-L1). No significant 
differences in mRNA expression of lung cytokines and chemokines were observed between 
treatment groups in the Phase II treatment time window study. There were no significant 
differences in RANTES, IL-13 and CC10 expression in the lung (Fig 12). 
 
Discussion 
 The antiviral mechanisms of hRSV therapeutic compounds can be classified into two 
distinct groups: 1) compounds that target viral entry and 2) compounds that target non-entry 
mechanisms of hRSV [29, 30]. HRSV is part of the family Pneumoviridae (formerly subfamily 
of Paramyxoviridae) [31] which have viral envelopes composed of three glycoproteins: fusion 
(F) protein and attachment (G) protein that function in viral attachment and entry, and small 
hydrophobic (SH) protein that serves as an ion channel. Interestingly, previous testing has 
shown that fusion protein is indispensable for viral entry into the host cells while deletion of 
G protein produced a replication-competent viral mutant [32]. A major group of antiviral 
compounds, fusion protein inhibitors, have been developed to block viral infection. The 
mechanism of inhibition by these small molecule fusion protein inhibitors is through high 
affinity binding at the trimeric ectodomain pocket of prefusion F protein and restricting 
movement into the post-fusion conformation resulting in the blockage of fusion of the viral 
envelope to the host cell membrane [18, 19]. The capability of viral escape mutation from these 
fusion inhibitors has been identified in laboratory setting [33]. Furthermore, the most effective 
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time to administer this group of compounds is when given as a prophylactic treatment or within 
the first 24 hours after infection, since the mechanism of antiviral activity involves blocking 
the early steps of viral entry and fusion [19] although the results from this lamb study 
demonstrated pronounce reduction of hRSV-associated lung lesions and 5-fold reduction of 
virus in BALF samples when administered at 3 dpi.  
Once the virus enters the cell, the non-entry antiviral hRSV replication inhibitors are 
prime therapeutic candidates for late-onset treatment of viral infection. Replication inhibitors 
target various specific machinery required for viral replication including nucleoside inhibitors 
[34] and nucleoprotein inhibitors [35, 36]. The hRSV replication inhibitor tested with the 
HuAEC model was found to be effective when administered at 72 hours post-infection which 
is a prolonged time window for treatment compared to the fusion inhibitor [20]. A non-fusion 
inhibitor anti-hRSV compound, JNJ-64166037, has also been tested in lamb model of hRSV 
and had pronounced antiviral activity with daily oral administration starting at 1h post infection 
[37]. Treatment with a fusion inhibitor that blocks the early phase of viral entry in combination 
with a replication inhibitor that prevents further viral replication would be beneficial in 
enhancing the reduction of viral load and useful in clinical settings where the infection timeline 
is imprecise. Administration of a combination of antiviral drugs with different modes of action 
has been shown to optimize following infection with influenza virus [38], hepatitis B virus 
[39], hepatitis C virus [40] and human immunodeficiency virus [41]. Reports describe the 
benefits of combination delivery of an immunotherapeutic compound and an antiviral 
nucleoside inhibitor for patients at high risk for hRSV infection [42, 43]. To the extent of our 
knowledge, this is the first preclinical in vivo experiment of combination small molecule 
antiviral therapy against hRSV infection. 
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In this lamb model study, lack of alterations in the plasma concentration of fusion and 
replication inhibitor compounds were observed in combination treatment compared to 
monotherapy treatment administered at the equivalent dose. There were appropriate 
distributions of both fusion and replication inhibitor compounds in the lung and epithelial 
lining fluid with minimal differences in distribution between combination and monotherapy 
treatment. This indicates that there is less likelihood of interference in absorption, distribution 
and biometabolism process of this combination therapy. Outside of the work in this study and 
previous in vitro assays, little is known about the dynamics of the combination of these two 
compounds and therefore, future investigations and additional work are needed in order to 
advance this treatment regimen toward clinical trials and approval. Such studies could include: 
the compatibility of the formulations, drug-drug interactions and binding to endogenous 
protein and other molecules that may alter the pharmacokinetics, toxicity level, and 
biometabolism rate. 
Our findings demonstrate that the administration of a combination of a fusion inhibitor 
and replication inhibitor for hRSV reduced the viral load in the BALF and lung tissue samples 
and decreased the degree of hRSV-related lung lesions to a greater extent compared to fusion 
and replication inhibitor monotherapy. This result indicates the synergistic potential of 
combining these treatment compounds. The amount of virus and host inflammatory responses 
are the main factors contributing to the pathogenesis of hRSV infection and are associated with 
severity of the infection in human infants [44-47]. The quantification of hRSV viral level from 
BALF samples by RT-qPCR represents the entire lobe/lung airways and lacks drug carrying-
over effect that may be apparent with cell culture based viral titration. Interestingly, there was 
a pronounced decrease in the viral load and reduced pulmonary lesions with combination 
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therapy when the first dosage was administered at 3 and 4 dpi compared with fusion inhibitor 
monotherapy delivered at 3 dpi. In addition, monotherapy of replication inhibitor given at 3 
dpi significantly reduced the viral load, though the pulmonary lesions were decreased to a 
lesser extent compared to other therapeutic regimens. This indicates that there is an extended 
treatment time window of up to 4 days post-infection with anti-hRSV replication inhibitors 
and even more pronounced reduction of viral load and lesions when administering in 
combination with hRSV-fusion inhibitor. Thus, fusion and replication inhibitor combination 
therapy is a promising candidate for future treatment of hRSV infection. 
An innate immune response in the lung is essential for defense against hRSV infection 
in infants since their adaptive immune response is not fully developed. The first-line of defense 
against hRSV infection is the mucociliary apparatus that serves a physical barrier and 
antimicrobial products that coat the airways such as surfactant proteins (SP-A, SP-D), 
uteroglobin (CC10), DUOX/LPO oxidative system, defensins and cathelicidins [47]. There is 
also activation of pattern recognition receptors that upregulate the cellular immune components 
and upregulate the production of cytokines. The cytokine components of hRSV infection are 
associated with regulating the balance of host immune response which is important in the 
disease outcome of hRSV infection [48]. A set of cytokines were analyzed in hRSV-infected 
lamb lungs at day 6 post-infection and we found significantly increased mRNA expression of 
CXCL10 (IP-10), CCL2 (MCP-1), CCL3 (MIP-1α), CD274 (PD-L1) and IFN-λ. The 
chemokines CXCL10 (IP-10 ), CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES) are 
responsible for chemoattraction of cellular inflammatory components in the lung which have 
shown increased levels in infants with severe hRSV bronchiolitis [49]. Overall, the chemokine 
profile of lambs infected with hRSV strain M37 in this study was consistent with previous 
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reported data of inflammatory response in neonatal lambs infected with hRSV strain A2 [50, 
51]. Interestingly, CCL5 (RANTES) in hRSV-infected lambs did not appear to significantly 
decrease at 6 dpi. The explanation for a lack of RANTES (CCL5) expression could be due to 
a host defect in production or direct viral blockage, although this still remains inconclusive. 
The expression of T cell regulatory ligand, PD-L1 (CD274) was elevated in hRSV-infected 
neonatal lamb model at 6 dpi which was also consistent with previous reported data [50]. This 
elevation of PD-L1 (CD274) level may play a role in the inactivation of cytotoxic T cell 
response against hRSV infection which was observed in other model studies [52, 53]. 
The main method of immunomodulation mediated by hRSV is through the hRSV 
nonstructural protein (NS1/2) which reduces the signaling of type I interferon (IFN/) 
production [54]. Low levels or lack of IFN/ was detected in nasal or bronchoalveolar lavages 
from infants infected with hRSV [55, 56]. Similar reports were observed in hRSV-infected 
neonatal lamb model [50]. Nevertheless, type III interferon (IFN-λ) had detectable increase 
with hRSV infection observed in well-differentiated pediatric primary bronchial epithelial cell 
cultures (WD-PBECs) [57], suggesting its role in antiviral response. A similar pattern of 
predominant type III interferon response was reported in other respiratory paramyxoviruses 
including measles and mumps in humans [58]. These results indicate the potential of hRSV-
infected lamb model for studying viral interferon responses, effect of antiviral treatment on 
interferon response [59] and future antiviral interferon therapy.  
Administration of combination drug therapy against hRSV has a promising potential 
candidate for the treatment option of both early and late detection of hRSV infection. This 
combined treatment had potent antiviral effects in the hRSV-infected lamb model and 
demonstrated an extended time window for treatment up to 4 days after infection. The 
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combination treatment regimen also offers a potential barrier to the evolution of escape mutants 
compared to monotherapies. Furthermore, the neonatal lamb model of hRSV infection appears 
useful for testing antiviral therapeutic compounds. 
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Figure 1: Pharmacokinetics of fusion and replication inhibitors in Phase I combination efficacy 
study  
The small molecule inhibitor compound levels were measured in the lung (top left) and 
epithelial lining fluid (ELF) (top right) at day 6 post-infection. The fusion (middle) and 
replication (bottom) inhibitor concentrations in the plasma of treatment groups were evaluated 
at different time points. The time of treatment administration is indicated by the dotted lines.
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Figure 2: Pharmacokinetics of fusion and replication inhibitors in Phase II treatment time 
window study 
The small molecule inhibitor compound levels were measured in the lung (top left) and 
epithelial lining fluid (ELF) (top right) at day 6 post-infection. The fusion (middle) and 
replication (bottom) inhibitor concentrations in the plasma of treatment groups were evaluated 
at different time points. The time of treatment administration is indicated by the dotted lines.   
 133 
 
Figure 3: Phase I combination efficacy study viral titer in BALF and lung detected by FFU 
and RT-qPCR  
Levels of viral titer in BALF (top left) and lung (top right) detected by FFU and viral RNA 
detected in BALF (bottom left) and lung (bottom right) by RT-qPCR in different treatment 
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Figure 4: Phase II treatment time window study viral titer in BALF and lung detected by FFU 
and RT-qPCR  
Levels of viral titer in BALF (top left) and lung (top right) detected by FFU and viral RNA 
detected in BALF (bottom left) and lung (bottom right) by RT-qPCR in different treatment 









































Figure 5: Clinical parameters assessment in Phase I and Phase II combination study 
MeanSD of body temperature, respiratory rate, heart rate and body weight of the lambs 
measure once daily throughout the Phase I efficacy study (top); combination high dose (TxH), 
combination low dose (TxL), fusion inhibitor (TxF), non-fusion inhibitor (TxR) and RSV-
infected non-treatment group (RSV), and Phase II treatment time window study (bottom); low 
dose combination given at 3 dpi (TxL3),  fusion inhibitor given at 3 dpi (TxF3), non-fusion 
inhibitor given at 3 dpi (TxNF3) and high dose combination given at 4 dpi (TxH4).  










































































































































































Figure 6: Macroscopic lesions of lungs from Phase I combination efficacy study 
Macroscopic lesions of lungs from the combination efficacy study (Phase I); (6a) RSV, (6b) 
TxH, (6c) TxL, (6d) TxF, and (6e) TxNF. Average percentages of lung lesion are compared in 
the graph (bottom right). 
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Figure 7: Microscopic lesion in lungs of Phase I combination efficacy study 
Pulmonary histopathological changes in lungs from the combination efficacy study (Phase I); 
(7a) RSV, (7b) TxH, (7c) TxL, (7d) TxF, and (7e) TxNF. Average percentages of microscopic 



























Figure 8: Immunohistochemical detection of RSV antigen and in situ hybridization 
detection of hRSV mRNA in lamb lungs from Phase I combination efficacy study 
 
Immunohistochemical (8a, 8c, 8d, 8g, 8f) and RNA in situ hybridization (8b, 8e, 8f, 8i, 8j) of 
hRSV in different treatment group of Phase I combination efficacy study; RSV (8a, 8b), TxH 
(8c, 8e), TxL (8d, 8f), TxF (8g, 8i), and TxNF (8h, 8j). The average level of hRSV detected 
with immunohistochemistry (bottom left) and RNA in situ hybridization (bottom right) is 












































Figure 9: Morphological lesions in the lung from Phase II treatment time window study  
Morphological lesions in the lung from the treatment time window study (Phase II); (9a, 9b) 




Figure 10: Macroscopic and microscopic hRSV-associated lung lesion from Phase II treatment 
time window study 
The degree of macroscopic (left) and microscopic (right) hRSV-associated lesion of different 
treatment groups evaluated at 6 days post-infection from the treatment time window study 




























Figure 11: Immunohistochemical detection of RSV antigen in situ hybridization detection of 
hRSV mRNA in lamb lungs from Phase II treatment time window study 
Immunohistochemical (11a-d) and RNA in situ hybridization (11e-h) of hRSV antigen 
detected in different treatment group of treatment time window study (Phase II); (11a, 11e) 
TxL3, (11b, 11f) TxF3, (11c, 11g) TxNF3, and (11d, 11h) TxH4. The average level of hRSV 
viral antigen detected with immunohistochemistry (bottom left) and RNA in situ hybridization 
(bottom right) is compared between different treatment groups.  
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Figure 12: Cytokine and chemokine mRNA expression (IP-10, MCP-1, MIP-1α, PD-L1, 






















































































































































































































































































































Phase I Combination Efficacy Study  
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Supplementary Table 1: Microscopic scoring criteria of hRSV infected lung evaluated. Two 
representative histological sections taken from each right cranial lobe, left cranial lobe, left 
middle lobe and left caudal lobe were examined per lamb. 
 
 
Score 1 2 3 4 
Microscopic alveolar 
consolidation (CS)* 





10-39% of evaluated 
region presented with 
alveolar 
consolidation 
40-69% of evaluated 
region presented with 
alveolar 
consolidation 
More than or equal to 
70% of evaluated 
region presented with 
alveolar 
consolidation 
Bronchiolitis (BR) Minimal detectable 
lesion (epithelial 
degeneration) in one 
or a few bronchioles 
per 200X field 
Epithelial 
degeneration 
involving less than 









of the airway lumen 















Up to three in three 
200x fields 






in one or a few per 
20x per field 
10% in multiple 
airways per field 
10-50% in multiple 






in one or a few 
airways per 20X 
field 
10% of airway per 
field 
10-50% in multiple 




Minimally detectable 10 or less neutrophils 
in one or a few 
airways/alveoli 
10 or more 
neutrophils in several 
airways/alveoli 














infiltrates that expand 
more than three cells 
wide 
Circumferential 













infiltrates that expand 
more than three cells 
wide 
Circumferential 
infiltrates that for 
nodules. 
* CS scoring is based on evaluation of 20, 200X field per slide (field number 22) with a single slide containing two lung 






Supplementary Table 2: List of RT-qPCR forward primers, reverse primers and probes 
sequences for each target. 
 



























RANTES 5'-TGCTTCTGCCTCCCCATATG 5'-GGGCGGGAGATATAGGCAAA 6FAM-CACCACGCCCTGCT-
MGBNFQ 
IL-13 5'-CAGCCCTGGACTCCCTGAT 5'-CCTCTTGGTCCTGTGGATGAC 6FAM-AGCATCTCCAACTGC-
MGBNFQ 









CHAPTER 5.    GENERAL CONCLUSIONS 
Suitable methods for prevention, treatment and control of human respiratory syncytial 
virus (hRSV) infection are needed. Currently, no vaccine or therapy has proven to be fully 
successful and none have advanced pass all required clinical trials. In hopes for future disease 
alleviation, many antiviral compounds have been tested in laboratory settings and animal 
models to identify promising drug candidates for hRSV treatment. The main goal of this 
dissertation was to assess the therapeutic efficacy of orally administered small molecule 
inhibitor(s) against hRSV in newborn lambs as a model of hRSV infection and bronchiolitis 
infants. 
In Chapter 2, we described in detail the method for evaluating orally administered small 
molecule antiviral compound to hRSV-infected lambs and demonstrated the therapeutic 
efficacy of hRSV fusion protein inhibitor, JNJ-53718678. We identified a reduction of 
pulmonary viral load and lung lesions in a dose-dependent manner and demonstrated a 
profound reduction with appropriate dosage when administered within the 24 hours post 
infection (hpi). This potent antiviral compound has good potential as a drug candidate and had 
advanced into the clinical trial phase. 
In Chapter 3 we explored another therapeutic target for the treatment of hRSV infection 
that inhibits viral replication. The small molecule replication inhibitor, JNJ-64166037, was 
administered orally to hRSV-infected lambs at 1 hpi. This compound effectively reduced viral 
load and pulmonary lesions in a dose-dependent manner, thus characterizing another potential 
antiviral therapeutic compound that inhibits a different stage of viral infection specifically at 
the viral replication cycle. In addition to the routine viral isolation assay, molecular assay and 
immunohistochemical staining to quantify and localize the hRSV antigen in the lungs of our 
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lambs, we performed a recently developed technique, RNA in situ hybridization (RNAscope) 
analysis on the lung tissues in order to identify cellular localization of RSV mRNA and 
estimate the density of virus in each cell. We were able to modify an RNAscope evaluation 
method (H scoring) using image analyzer software to efficiently quantify the amount of hRSV 
mRNA present in the lung tissue samples. 
The last part of this dissertation, Chapter 4, we administered combination antiviral 
treatment of fusion and replication inhibitors in lambs infected with hRSV in order to first, 
investigate the therapeutic efficacy compared to that of monotherapy, and second, to evaluate 
the treatment time window of compound administration. We determined that the combination 
treatment at 24 hpi was able to decrease the average viral load and lung lesion more extensively 
than single administration of fusion and replication inhibitors. In addition, administering the 
combination therapy at 3- and 4-days post-infection (dpi) demonstrated significant reduction 
of viral load and pulmonary lesions compared to monotherapy of fusion inhibitor at 3 dpi, 
indicating a wider window for treatment which is more practical in clinical settings. A new 
approach of cytokine expression analysis was applied in this study for the hRSV Memphis 37 
infected lambs, by combining the cytokines mRNA expression in the lung from multiple 
studies in the hRSV-infected positive control and non-infected negative control animals at 6 
dpi to create a profile and baseline of cytokines expression for future pathogenesis studies and 
comparison with treated animals. 
The research completed in this dissertation has shed some light towards potential 
treatments for hRSV infection and further demonstrated the potential of hRSV infected lambs 
as a model of hRSV infection in infants. Questions remain on the potency, dosage, safety, 
possible drug interactions when these compounds are administered with other compounds. 
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There are potential adverse drug reactions of these hRSV small molecule inhibitors when used 
in humans and infants as for any medication. These issues may be assessed and elucidated with 
advancement through multiple phases of clinical trials. Lambs infected with hRSV mimics 
hRSV infection in infants, but immunological responses by lambs could be further 
characterized through a complete kinetic assessment of cytokine profile response for different 
strains of hRSV and also the type of cellular immune response [1, 2], and long-term 
immunological changes in lamb lungs previously infected with hRSV. Moreover, some 
immunologic responses may prime lungs for asthma later in life and allergic reactions, both of 
which are reported in human infants [3-7]. Lambs may also be suitable for studies of other 
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